Published in final edited form as:

Future Med Chem. 2012 June ; 4(9): 1171–1207. doi:10.4155/fmc.12.74.

Potential implication of the chemical properties and bioactivity of nitron spin traps for therapeutics

Frederick A Villamena*, Amlan Das, and Kevin M Nash

Department of Pharmacology, & Davis Heart & Lung Research Institute, College of Medicine, The Ohio State University, Columbus, OH 43210, USA

Abstract

Nitron therapeutics has been employed in the treatment of oxidative stress-related diseases such as neurodegeneration, cardiovascular disease and cancer. The nitron-based compound NXY-059, which is the first drug to reach clinical trials for the treatment of acute ischemic stroke, has provided promise for the development of more robust pharmacological agents. However, the specific mechanism of nitron bioactivity remains unclear. In this review, we present a variety of nitron chemistry and biological activity that could be implicated for the nitron's pharmacological activity. The chemistries of spin trapping and spin adduct reveal insights on the possible roles of nitrons for altering cellular redox status through radical scavenging or nitric oxide donation, and their biological effects are presented. An interdisciplinary approach towards the development of novel synthetic antioxidants with improved pharmacological properties encompassing theoretical, synthetic, biochemical and *in vitro/in vivo* studies is covered.

Among the most important signaling molecules in biological systems are the reactive oxygen species/reactive nitrogen species (ROS/RNS). ROS/RNS are small molecules, comprising a handful of atoms that come as radical or nonradical species, as well as in neutral or ionic forms. As natural by-products of O₂ metabolism, ROS/RNS play an important role in modulating cell function, cell signaling and immune response [1-3]. ROS are mostly O₂ derived [4] while RNS are NO-derived species in which the oxygen and nitrogen atoms participate in the redox reaction, respectively [5]. While the names ROS and RNS imply their reactive nature, their reactivity varies with different substrates. For example, O₂^{•-} is practically unreactive with most amino acids, lipids or nucleotides but exhibits high reactivity with Fe-S clusters and other radicals such as tyrosyl and NO. The ability of ROS to cause post-translational protein modification results in changes in protein conformation and can have physiological consequences. For example, NO's ability to bind to the heme of soluble guanylate cyclase is the main mechanism of NO's vasodilatory effect in the vasculature. In cerebral arteries, activation of NADPH-oxidase causes production of O₂^{•-}, and O₂^{•-}-derived ROS results in increased vasodilation and may play a physiological role as a signaling molecule in cerebral circulation [6]. Redox regulation by ROS through

*Author for correspondence: Tel.: +1 614 292 8215, Fax: +1 614 688 0999, frederick.villamena@osumc.edu.

Financial & competing interests disclosure

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

reversible or irreversible modification of thiol groups via oxidation, which also includes disulfide formation, nitrosylation and glutathiolation, has tremendous consequences in anti- or pro-apoptotic signal transduction processes [7,8]. Under oxidative-stress conditions, ROS unregulated production or concentrations can cause oxidative damage to key biomolecular systems such as lipids, nucleotides, carbohydrates and proteins, which can have significant effects in maintaining the integrity of cellular structure, controlling gene induction and can cause enzyme deactivation. Among the mechanisms that can trigger oxidative stress are downregulation and/or deactivation of antioxidant enzymes, mitochondrial dysfunction, activation of NADPH oxidase, aberrant activation of NF- κ B and MAPK, and calcium signaling – all of which can result from ROS-mediated posttranslational protein modification. Oxidative stress most often results from the disturbance of the intracellular and extracellular redox environments, triggering a variety of events that can lead to apoptosis or necrosis. Oxidative stress has been implicated in the pathogenesis of cardiovascular diseases [9], cancer [10], neurodegeneration [11] and ischemic–reperfusion (I/R) injury [12,13], to name a few.

Antioxidant-based therapy based on *in vitro* observations has made some strides to minimize, prevent or ameliorate oxidative stress via a variety of different mechanisms, such as direct radical scavenging, bolstering of phase II enzyme expressions and/or activity, reversal of eNOS uncoupling or suppression of signal transduction and gene induction leading to apoptosis. Antioxidants can be categorized into subclasses of small molecules and macromolecules that are endogenously synthesized in the body, or exogenously introduced from diets. One of these classes is the antioxidant enzymes such as superoxide dismutase (SOD), catalase (CAT), heme-oxygenase, NAD(P)H dehydrogenase quinone 1, glutathione peroxidase and glutathione reductase. Due to the size of these molecules, high-molecular-weight therapeutics has been the strategy of choice for their efficient delivery to cells that form the blood–brain barrier. Through the use of nanoparticulate systems, such as liposomes or polymeric nanoparticles, antioxidant enzymes have been delivered to the cells imparting protective efficacies against oxidants. Poly(D,L,-lactide co-glycolide) polymer loaded with SOD was shown to protect cultured human neurons from H₂O₂-induced oxidative stress [14]. In *in vivo* models, immunotargeting using platelet–endothelial cell adhesion molecule antibodies conjugated to CAT showed immediate protective antioxidant effects in the pulmonary endothelium for the treatment of acute lung injury [15]. A gene therapy approach, however, can provide continuous delivery of the antioxidant enzymes at the site of the disease through just a single administration [16–18]. *In vivo* gene transfer of the cDNA encoding extracellular SOD exhibited substantial protection to the heart against myocardial stunning and decreased infarct size following myocardial infarction [19,20]. Inhibition of ROS-producing enzymes using small-molecule and peptide inhibitors has also shown promise in the treatment of vascular and renal dysfunctions [21]. For example, apocyanin, an NADPH oxidases inhibitor, has been employed in Type 2 diabetes rat models, showing reduction in markers of oxidative stress along with improvements in renal glomerular injury [22].

Small endogenously synthesized molecules such as α -lipoic acid (α -LA) have been shown to bolster antioxidant defenses through induction of phase II enzymes (e.g., heme-oxygenase) via stimulated translocation of Nrf2 [23]. Supplementation of α -LA has been

shown to ameliorate oxidative stress-associated insulin resistance in whole body and skeletal muscle in the obese rats [24]. Glutathione (GSH) is also one of the most ubiquitous small molecules present in biological systems. In humans, aerosolized thiols such as glutathione and *N*-acetylcysteine have been employed as therapeutic strategy against pulmonary cystic fibrosis to target inflammatory responses caused by neutrophil-dependent reactions catalyzed by myeloperoxidase [25].

Supplementation by diet-derived natural anti-oxidant vitamins has failed to reduce cardiovascular disease and has even been detrimental with single antioxidant therapy using vitamin E in clinical trials in adults [26]. Moreover, the use of vitamins E and C and β -carotene alone or in combination blunts the protective HDL2 cholesterol response to HDL cholesterol-targeted therapy and, therefore, can be harmful [27,28]. However, early detection and treatment with vitamins C and E in hyperlipidemic children has been promising showing restored endothelial function that may retard the development of atherosclerosis [29]. Several plant-derived antioxidants, including isoflavones, indole-3-carbinol and 3,3'-diindolylmethane, curcumin, epigallocatechin-3-gallate, resveratrol, lycopene and vitamins, exhibit inhibitory effect against oxidative stress and NF- κ B activation in the development of cancers [30].

The use of synthetic antioxidants is attractive as it becomes possible to manipulate their physicochemical properties as well as their target specificity to enzyme, organelle or cell type for optimal pharmacological activity [31]. Molecules containing multiple α -LA moieties forming liposomes can increase α -LA bioavailability [32]. Low-molecular-weight SOD mimetics show pharmacological potential with strong anti-inflammatory and cytoprotective properties [33], for example, the SOD/CAT mimetic, EUK-134, completely abolished the H₂O₂-mediated ROS release as well as the incidence of arrhythmias in rat hearts [34]. Synthetic phenolic-based compounds such as isoeugenol [35] showed improved antioxidant capacity compared with trolox and butylatedhydroxytoluene, while hydroxylated resveratrol analogues [36] show selective inhibition of COX-2 *in vitro*. Ebselen, a synthetic lipid-soluble selenium-based compound shows glutathione peroxidase 1-mimetic properties with anti-inflammatory and antioxidant activities by inhibiting 5-lipoxygenase, NOS, NADPH oxidase, PKC and ATPase activities [21]. Iron chelators have also shown promise as therapeutic agents, since evidence show that iron accumulates at the sites of tissue deterioration and, therefore, relieving iron overload at these sites is important [37-39]. Iron, through Fenton-type reactions, can generate radicals, therefore their sequestration can be an effective strategy to prevent oxidative damage to cellular systems. In neurodegenerative diseases, it has been shown that iron chelators not only suppress radical production, but also promote stabilization of HIF-1 α and increase transcription of HIF-1-related survival genes – important for its neuroprotective effects [40].

Mitochondrial dysfunction has been implicated in the early development of diseases. Therefore, drugs that target the innermitochondria membrane agents through the use of electron acceptors, electron donors and hydride acceptors can be an effective therapeutic strategy [41]. Using nitroxides conjugated to a modified gramicidin S moiety, triphenylphosphonium lipophilic cationic compounds, sulfonyleureas, anthracyclines, SS tetrapeptides with 2',6'-dimethyltyrosine moiety, or to mitochondria-specific proteins/lipids,

were successfully used in preventing superoxide radical production in cellular systems and in protecting cells against apoptosis [41]. Nitroxides have found therapeutic applications by altering tissue redox status and have the ability to alter many metabolic processes [42,43]. Although nitroxides impart SOD-mimetic properties, in biological systems they can be rapidly reduced to hydroxylamines by enzymes such as CYP450 and nitroreductases. Nitroxide specificity to radicals is dependent on their structure, cellular compartmentalization property and rate of bio-reduction. Since SOD is ubiquitous in cells, the nitroxide mode of action is only relevant under conditions where the $O_2^{\bullet-}$ flux overwhelms that of SOD. For example, in conditions of ionizing radiation, nitroxides can serve as protective agents against radiation-induced oxidative damage via their direct reaction with radicals.

Application of nitrones as potential pharmacological agents was proposed by Novelli *et al.*, demonstrating that administration of α -phenyl-*tert*-butyl nitron (PBN) confers protection on rats from lethal whole-body trauma or circulatory shock [44,45]. Due to their efficacy in trapping free radicals generated inside the cells and tissues, nitrones have been used as pharmacological agents against several ROS-related disorders, such as brain injury [46,47], renal injury [48], visual loss [49], neuronal damage [50] and other age-related diseases [51]. The PBN derivative 2,4-disulphophenyl-*N-tert*-butylnitron, referred to as **NX-059**, was the first compound to reach Phase III clinical trials in the USA for the treatment of acute ischemic stroke [52]. Very recently, the cardio-protective functions of the cyclic nitron, 5,5-dimethyl-1-pyrroline *N*-oxide (**DMPO**), against I/R injury have been reported [53]. The anticancer role of PBN and its derivatives against various types of cancer is also well documented [54,55]. The PBN-derived nitrones are reported to inhibit tumor growth and progression in hepatocellular carcinoma [56,57], brain cancer [58,59] and colon cancer [60] models. However, experimental evidence suggests other mechanisms for its protection are involved other than its free radical-trapping ability. Aside from the free radical-scavenging property of nitrones, PBN and DMPO exhibit NO-releasing properties [61,62], which may be partly responsible for their pharmacological properties.

What are nitrones?

Nitrones are *N*-oxides of imines with a general formula of $R_1R_2C=NR_3^+O^-$ (where R_1 , R_2 , R_3 = any alkyl group; R_1 or R_2 = H). Nitrones have been widely employed as synthetic intermediates [63] and as a spin-trapping reagent for the detection of radicals in solution [64]. Nitron chemistry parallels that of carbonyl compounds in which the nitronyl-carbon (α -carbon) (Figure 1) is susceptible to nucleophilic attack. Another unique property of nitrones is their ability to undergo a cycloaddition reaction, a property that has been widely exploited in the synthesis of more complex organic molecules [65].

Nitrones can undergo a radical addition reaction to form an aminoxyl-based paramagnetic adduct that is persistent enough to be detected by electron paramagnetic resonance (EPR) spectroscopy (Figure 2), and has become a popular analytical tool for the detection of radicals in chemical and biological systems [66], and in the synthesis of polymers [67].

To date, there are two major types of spin traps, the cyclic (DMPO and 5-diethoxy-phosphoryl-5-methyl-1-pyrroline *N*-oxide [DEPMPO]) and linear (PBN and NXY-059) forms (Figure 3). EPR spin trapping using DMPO has undoubtedly contributed significantly towards the understanding of some important free radical-mediated biochemical processes [68-72]. Nitrones have also found application in the fields of photodynamic therapy [73,74], fuel cell research [75], nanotechnology [76] and catalysis [77].

Importance of superoxide radical scavenging

Superoxide radical ($O_2^{\bullet-}$) is a paramagnetic and anionic molecule formed from the one-electron reduction of triplet oxygen and is a major precursor of the most highly reactive species known to exist in biological systems (Figure 4). Superoxide can undergo further reduction to form ROS, causing oxidation of proteins, carbohydrates, lipids and DNA. Therefore, formation of $O_2^{\bullet-}$ signals the first sign of oxidative burst and, therefore, its detection and/or sequestration in biological systems is important.

Superoxide can be enzymatically generated in biological systems from NO synthase uncoupling [78], stimulation of NADPH oxidase [79], CYP450 [80], FAD-containing monooxygenase [81], xanthine oxidase [82], or electron leakage from the mitochondrial electron transport chain (ETC) complexes [83]. Chemically, $O_2^{\bullet-}$ can also be formed directly from alkali metal salts (NaO_2 and KO_2), or from redox cycling xenobiotics [84], photosensitization of quinones [85,86] and water-soluble fullerene C_{60} [87]. In chemical and biological systems, $O_2^{\bullet-}$ itself is generally poorly reactive, showing high reactivity to only a few species such as tyrosyl radicals, metal ions and metalloproteins (e.g., aconitase), making $O_2^{\bullet-}$ perhaps a more detrimental oxidant due to its reaction selectivity [88].

Traps versus probes

One can make a generalization that all spin traps are redox probes, but not all redox probes are spin traps. EPR spectroscopy exploits the magnetic moment of an unpaired electron where the absorption of microwave radiation by the unpaired electrons as a function of magnetic field strength is measured. EPR spectroscopic detection of $O_2^{\bullet-}$ can either involve spin-quenching (or spin-loss) or spin-formation techniques where loss or formation of a signal is measured, respectively (Figure 5). An example of the spin-quenching method is through the use of the triarylmethyl (trityl)-based radical, which is considered an 'inert' free radical because of its inherent stability [89,90]. The redox reaction of trityl with $O_2^{\bullet-}$ yields molecular oxygen and the EPR silent trityl anion. The synthetic trityl radicals TAM OX063 and perchlorotriphenylmethyl (PCM-TC) have been shown to give high reactivity to $O_2^{\bullet-}$ with second-order rate constants of $3.1 \times 10^3 \text{ M}^{-1} \text{ s}^{-1}$ and $8.3 \times 10^8 \text{ M}^{-1} \text{ s}^{-1}$, respectively [89,90]. Trityl radicals show inertness toward a majority of the common oxidoreductant species; however, they exhibit reactivity with other radical species, such as $HO_2^{\bullet}$, $RO_2^{\bullet}$ and $HO^{\bullet}$ [90].

A spin-generating system uses a diamagnetic probe that, upon its reaction with a free radical, forms an EPR-detectable paramagnetic species. Nitrones and hydroxylamines fall under this category. Original research on enzyme-catalyzed oxidation of hydroxylamines to

nitroxides dates back to 1977 [91,92]. Hydroxylamines are *N*-hydroxy-pyrrole or piperidine derivatives that are able to undergo oxidation by $O_2^{\bullet-}$ via a simple electron transfer mechanism to yield a para-magnetic aminoxyl species and H_2O_2 . The commonly used hydroxylamines TEMPONE-H, CP-H and PP-H are able to extracellularly or intracellularly scavenge $O_2^{\bullet-}$ radicals [93,94]. The rate of hydroxylamine oxidation is dependent on structure. In the case of PP-H, its rate of reaction to $O_2^{\bullet-}$ was found to be $840 \pm 60 M^{-1} s^{-1}$. Although the hydroxylamine PP-H was shown to have tenfold higher reactivity with $O_2^{\bullet-}$ than the nitron DEPMPO, the paramagnetic species generated does not allow discrimination between the different radicals generated since this reaction is not specific to $O_2^{\bullet-}$ and other radicals can cause one-electron oxidation of the hydroxylamine. Moreover, the H_2O_2 generated from the redox reaction can lead to the production of other ROS and is, therefore, susceptible to false interpretation [95]. Addition of SOD can serve as control, but in many biological systems this is not possible.

Nitrones, however, can undergo addition of a free radical at the α -carbon (C-2) to form an aminoxyl product in which the unpaired electron is almost equally distributed between the N and O atoms (Figure 6).

By virtue of resonance stabilization between the aminoxyl-O and -N (with a stabilization energy of $G_{298K} \sim 30$ kcal/mol) [96], the spin adduct is more persistent than the transient free radical being trapped, thus allowing for their spectrum to be observed by EPR. The spectra arising from various radical adducts allow for their discrimination due to the characteristic spectral profiles they exhibit and is by far a better technique in identifying specific free radicals. For example, DMPO-OOH exhibits a unique 12-line EPR spectrum compared with the four-line EPR spectrum for DMPO-OH, the latter nitroxide may be derived from the reduction of DMPO-OOH by glutathione (GSH) [97]. Spin trapping has also been employed to detect enzymatically generated $O_2^{\bullet-}$, such as from xanthine oxidase [98], the mitochondrial ETC [83,99], thioredoxin reductase [100] and NADPH oxidase [101]. Nitrones have also been successfully used to detect $O_2^{\bullet-}$ generation in human epithelial cells [102], human neutrophils [103], reperfused cardiac tissue [104] and, as a secondary radical adduct from small animals using an *ex vivo* technique [105]. *Ex vivo* spin trapping was best exemplified through the I/R studies of Boll and colleagues [106], and Zweier *et al.* [107] in which the spin trap was administered to the animals before the onset of ischemia. The reperfusates were then collected and radical adduct generation was detected by EPR spectroscopy.

Like other probes mentioned above such as trityl and hydroxylamine, nitron spin traps are also susceptible to the formation of artifactual adducts, which can be generated via nonradical addition mechanisms to nitrones. There are three accepted nonradical pathways for the formation of spin adducts: direct addition of nucleophiles to nitrones to form the hydroxylamine and subsequent oxidation to nitroxide mainly by O_2 ; metal-catalyzed (typically by Fe^{2+} or Cu^+) nucleophilic addition reaction to nitrones and subsequent electron-transfer with the metal; inverted spin trapping in which the nitron is initially oxidized to the radical cation and addition of nucleophile forms the nitroxide. The nucleophilic addition/oxidation is usually referred to as the Forrester–Hepburn mechanism and is a common source of spin adduct artifacts in aqueous solution [108,109]. However,

control experiments through the use of chelating agents, such as SOD or CAT, can well differentiate such nonradical addition mechanism from the actual spin trapping reaction. In *in vivo* systems, the formation of nitron-sulfite spin adduct was observed although the exact mechanism of the adduct formation is still a matter of controversy but nevertheless important in sulfur dioxide-exposure detoxification [110].

Reactivity of nitrones to superoxide

One direct proof for the reaction of nitrones with $O_2^{\bullet-}$ is through EPR spin trapping, which continues to be the most unequivocal detection technique for $O_2^{\bullet-}$ due to the distinctive EPR spectrum that the $O_2^{\bullet-}$ adduct imparts (Figure 7) compared with other radical adducts [111,112]. The limitations encountered using spin traps for the detection of $O_2^{\bullet-}$ is the slow reactivity of $O_2^{\bullet-}$ addition to nitrones, lack of target specificity making it difficult to identify the site of radical production in the cell and short adduct half-life, which limits their detectability. The first two limitations are important for the therapeutic applications of nitrones and efforts to overcome these problems will be discussed in detail in the following sections.

Why do nitrones trap superoxide radicals poorly?

From a purely thermodynamic standpoint, the order of increasing favorability as expressed by the free energies of reaction ($G_{rxn, aq, 298K}$ [kcal/mol]) for the addition of different radicals to nitrones in general is: NO (14.1) < $O_2^{\bullet-}$ (10.0) < $HO_2^{\bullet}$ (-7.0) < $HS^{\bullet}$ (-13.6) < $\bullet CH_3$ (-32.9) < $HO^{\bullet}$ (-38.9). The σ -type radicals (e.g., $HS^{\bullet}$, $\bullet CH_3$ and $HO^{\bullet}$) have exhibited higher reactivity compared with the π -type radicals, NO , $O_2^{\bullet-}$ and $HO_2^{\bullet}$ [113-116]. This mirrors the computational findings by Boyd and Boyd [117] where the order of increasing formation energies for the nitroso $HN=O$ spin adducts (in kcal/mol) is: NO (-7.8) < $HO_2^{\bullet}$ (-8.4) < $HS^{\bullet}$ (-21.5) < $HO^{\bullet}$ (-32.6) < $\bullet CH_3$ (-53.9); and for $CH_3N=O$ in kcal/mol is: NO (-8.1) < $HO_2^{\bullet}$ (-7.5) < $HS^{\bullet}$ (-18.2) < $HO^{\bullet}$ (-35.8) < $\bullet CH_3$ (-50.1) at the MP2/6-31G(d,p)//HF/6-31G(d) level of theory.

In general, this trend in reactivity follows the order of the degree of spin density residing on the attacking atom of the radical; that is, 100% spin density on the O, S and C atoms of $HS^{\bullet}$, $\bullet CH_3$ and $HO^{\bullet}$, compared with 70% (N), 50% (O) and 73% (terminal O) spin density distribution in NO , $O_2^{\bullet-}$ and $HO_2^{\bullet}$, respectively. The same partial electrostatic effect on radical reactivity was also observed for the radicals; that is, $HO^{\bullet}$ (O, -0.50 e), $\bullet CH_3$ (C, -0.58 e), $HS^{\bullet}$ (S, -0.12 e), $HO_2^{\bullet}$ ($O_{terminal}$, -0.15 e), $O_2^{\bullet-}$ (O, -0.50 e) and NO (N, +0.20 e). Table 1 shows the charge and spin (where applicable) densities of $HO^{\bullet}$, $O_2^{\bullet-}$, $HO_2^{\bullet}$, HO_2^- and HO^- , as well as the free energies of their addition to DMPO. In general, addition of anions is endoergic compared with radical addition to nitrones, with the exception of $O_2^{\bullet-}$. Although both $O_2^{\bullet-}$ and $HO^{\bullet}$ have the same charge density (i.e., 0.50 e) on the O-atom, the higher spin density distribution on the hydroxyl-O than superoxide-O makes $HO^{\bullet}$ more reactive than $O_2^{\bullet-}$, indicating the partial electrophilic character of radical addition to nitrones. As shown in Table 2 [118-120], this electronic property of the radicals determines their redox properties. Therefore, both charge and spin density distribution on the attacking atom govern radical reactivity to nitrones.

The thermodynamic trend in radical reactivity to nitrones parallel that of the apparent rate constants. For example, experimental rate constants for the reaction of DMPO with radicals are (HO•) [121]: $1.93 \times 10^9 \text{ M}^{-1} \text{ s}^{-1}$; (CH₃•CHOH) [122]: $1.1 \times 10^6 \text{ M}^{-1} \text{ s}^{-1}$; (glutathionyl radical GS•) [123]: $2.6 \times 10^8 \text{ M}^{-1} \text{ s}^{-1}$; and (O₂•⁻) [124,125]: $10\text{--}50 \text{ M}^{-1} \text{ s}^{-1}$. The rate constant for the trapping reaction of BocMPO with O₂•⁻ at pH 7.0 was reported to be $75.0 \pm 10.5 \text{ M}^{-1} \text{ s}^{-1}$, while at pH 5.0, when HO₂• is predominant, the rate constant is $239.2 \pm 10.5 \text{ M}^{-1} \text{ s}^{-1}$ [126].

Effect of nitronyl-C (or C-2) charge density on its reactivity to superoxide

The nucleophilic nature of O₂•⁻ reaction to nitrones (Figure 8) is demonstrated in Figure 9 where the charge density on C-2 for various C-5-substituted nitrones was correlated to the calculated kinetics and thermodynamics of O₂•⁻ addition to these nitrones [127].

The formation of O₂•⁻ adducts from the mono-substituted *N*-methylamide nitrones (AMPO, MAMPO and EMAPPO), and that of TFMPO are the most kinetically favored at the mPW1K level of theory, while DEPMPO gave the slowest rate constant, followed by DMPO, DiMAMPO and CPPO. Intermediate rate constants were predicted for the alkoxycarbonyl-substituted nitrones, EMPO and DEPO, and for the lactone CPCOMPO and the lactam TAMPO. The favorable formation of O₂•⁻ adducts in *N*-monoalkylamide nitrones is due to the relatively high positive charge on the C-2 position, as well as the early formation of hydrogen bonding interaction in the transition state between the amide-H and the O₂•⁻, thereby facilitating the formation of the O₂•⁻ adduct. These data suggest that the use of 5,5-disubstituted nitrones with electron-withdrawing alkoxycarbonyl and monoalkylcarbamoyl substituents could be ideal multifunctional spin traps in which target-specific and adduct-stabilizing moieties can be tethered in the parent nitron molecule employing ester or amide units as linker groups.

While the common nitrones, DMPO and PBN, are able to trap O₂•⁻, the measured rates of adduct formation are too low. In the case of PBN, the PBN-OOH adduct is not observed due to its instability (half-life <1 min) [124]. The trend in O₂•⁻ reactivity observed with PBN derivatives may not follow that observed with DMPO derivatives due to differences in the electronic property of their respective nitronyl-carbons. Results show that these reactions do not correlate with the calculated charge densities on the nitronyl-carbon for PBN derivatives. It was assumed that due to the higher observed electron density on the nitronyl-carbon in PBN derivatives compared with DMPO derivatives, the nature of O₂•⁻ addition to PBN may be considered as a borderline case (i.e., partly electrophilic), which explains the observed non-correlation between the rate constants and charge densities for the PBN derivatives [128].

Effect of the presence of hydrogen bond donors on the nitron reactivity to superoxide

The spin and charge density distribution on the O₂•⁻ and HO₂•, and their short O-O bond distances of 1.33 Å, are characteristics of a π-radical. By virtue of symmetry, the charge and spin density distribution on the two oxygen atoms of O₂•⁻ are equivalent; but addition of a proton to one of the oxygens to form HO₂• perturbs the electronic and charge distribution between the two oxygen atoms, resulting in higher spin density on the terminal oxygen atom

(73%) compared with the oxygen atom (35%) bound to the hydrogen atom (Table 1 & Figure 10). This polarization in the charge and spin density distribution in $\text{HO}_2^{\bullet}$ can have a significant effect on its reactivity, as shown by the difference in the reduction potentials between $\text{O}_2^{\bullet-}$ and $\text{HO}_2^{\bullet}$ of $E^{\circ} = 0.94$ and 1.06 V [4], respectively, in which the latter is more oxidizing than the former. Hydrogen bond interaction of $\text{O}_2^{\bullet-}$ with hydrogen bond donors such as amides serve as an initial 'anchor' for $\text{O}_2^{\bullet-}$ prior to its addition to the nitrone (Figure 10). Superoxide complexation with 1-methyl-1-carbamoylcyclopentane gave calculated favorable $G_{\text{rxn},298\text{K,aq}}$ and $H_{\text{rxn},298\text{K,aq}}$ of -4.1 and 4.7 kcal/mol, respectively. This interaction has a significant effect on the electronic property of $\text{O}_2^{\bullet-}$ in which it can assume a spin and charge density distribution intermediate to that of uncomplexed $\text{O}_2^{\bullet-}$ and $\text{HO}_2^{\bullet}$. We hypothesized that the presence of hydrogen bond donors, in general, may affect the rate of $\text{O}_2^{\bullet-}$ addition to nitrones in which the $\text{O}_2^{\bullet-}$ hydrogen bonding interaction with nitrones can exhibit reactivity close to that of a hydroperoxyl radical ($\text{HO}_2^{\bullet}$) [127].

Increased favorability (both kinetically and thermodynamically) of $\text{O}_2^{\bullet-}$ addition to nitrones in the presence of amide substituents compared with methyl, ester or phosphoryl substituents was observed [127]. It was later concluded that factors such as intramolecular hydrogen bonding of $\text{O}_2^{\bullet-}$ in the transition state and electrostatic effects facilitate the $\text{O}_2^{\bullet-}$ adduct formation [127]. The phenomenon called α -effect plays an important role in increasing $\text{O}_2^{\bullet-}$ reactivity upon hydrogen bonding. α -effect is exhibited by a class of nucleophiles that have an electronegative atom (with one or more lone pair of electrons) adjacent to the nucleophilic center called α -nucleophiles [129,130]. α -nucleophiles tend to be very strong electron donors and yet are very weak bases due to the inductive effect of the heteroatom adjacent to it. This high activity is due to the repulsive interactions between the unshared electron pairs on adjacent atoms between the lone pair of electrons on the α -atom and those on the nucleophilic center. This makes an α -nucleophile unstable and, hence, more reactive [129].

Further conjugation of the nitrone spin traps with β -cyclodextrin (CDNMPO [131] and $\text{C}_{12}\text{CDMPO}$ [132]) or calix[4]pyrrole [133], using amide or ester linker groups, respectively, can further enhance the spin-trapping ability and bioavailability of the nitrones. For example, CDNMPO, $\text{C}_{12}\text{CDMPO}$ and CalixMPO gave improved rates for spin trapping of $\text{O}_2^{\bullet-}$ and longer $\text{O}_2^{\bullet-}$ -adduct half-lives. The spin-trapping rates have been determined to be 58 (CDNMPO) [131], 221 ($\text{C}_{12}\text{CDMPO}$) [132] and 680 (CalixMPO) [133] $\text{M}^{-1}\text{s}^{-1}$, and improved their respective $\text{O}_2^{\bullet-}$ adduct half-lives ($t_{1/2}$), which are CDNMPO: 6 min, $\text{C}_{12}\text{CDMPO}$: 9 min and CalixMPO: 25 min in DMSO compared with DMPO alone, which has a rate constant of only $2 \text{ M}^{-1}\text{s}^{-1}$ and $\text{O}_2^{\bullet-}$ adduct half-life of 6 min in DMSO [133]. The high reactivity of $\text{O}_2^{\bullet-}$ to CalixMPO was rationalized to be due to a synergistic effect from the polarization of $\text{O}_2^{\bullet-}$ through hydrogen bonding with calix[4]pyrrole, enhanced positivity of the nitronyl-C through hydrogen bonding of the nitronyl-O and proximity of the nitrone group to the calix[4]pyrrole via conjugation (Figure 11).

The same behavior was observed for $\text{O}_2^{\bullet-}$ with various amino acids, which shows strong hydrogen bond interactions with the amino, carboxylic acid and guanidinium hydrogens [134]. These hydrogen bonding interactions result in significant perturbation of the spin and charge densities of the $\text{O}_2^{\bullet-}$. The low endoergicity of the free energies and exoergicity of the

enthalpies of complexation of $O_2^{\bullet-}$ with amino acids may translate to a favorable complex formation in solution. Ramification of $O_2^{\bullet-}$ hydrogen bonding towards facilitation of its addition to tyrosyl radical (TyrO $\cdot$) to form tyrosyl hydroperoxide had been demonstrated by Winterbourn *et al.* [135], where it was shown that there is an increase in tyrosyl hydroperoxide formation in peptides containing an amino group, such as lysine, which is adjacent to the tyrosyl group. The same enhancement in tyrosyl hydroperoxide formation was observed in the presence of free lysine or ethanolamine [135]. It is, therefore, reasonable to assume that $-NH-O_2^{\bullet-}$ complex formation may play an important role in the facilitation and selectivity of $O_2^{\bullet-}$ addition to TyrO $\cdot$ in protein systems, especially when these hydrogen bond donors are in close proximity to the TyrO $\cdot$ group.

Effect of pH on the nitron reactivity to superoxide

The original research on the pH dependence of rate of $O_2^{\bullet-}$ trapping was first investigated by Finkelstein *et al.* [124]. The mechanism of nitron antioxidant activity is intriguing, since at neutral pH, the reactivity of $O_2^{\bullet-}$ to DMPO is slow, with a second-order rate constant of only $2.0\text{ M}^{-1}\text{ s}^{-1}$; however, at acidic pH the reactivity is approximately $27\text{ M}^{-1}\text{ s}^{-1}$ or $10^3\text{ M}^{-1}\text{ s}^{-1}$ at pH 6.2 [136] and 5.0 [124], respectively. The high reactivity of $O_2^{\bullet-}$ to DMPO in acidic pH was proposed to be due to the protonation of $O_2^{\bullet-}$ to form hydroperoxyl radical ($HO_2\cdot$), since the pK_a for $O_2^{\bullet-}$ and $HO_2\cdot$ is 4.8 [137] and 4.4 [138], respectively, and that $HO_2\cdot$ is a stronger oxidizer than $O_2^{\bullet-}$ ($E' = 1.06$ and 0.94 V , respectively) [4]. The higher reactivity of $HO_2\cdot$ to DMPO compared with $O_2^{\bullet-}$ was theoretically rationalized and the predicted rate constants in aqueous phase for the $O_2^{\bullet-}$ and $HO_2\cdot$ addition to DMPO were found to be $5.9 \times 10^{-5}\text{ M}^{-1}\text{ s}^{-1}$ and $285\text{ M}^{-1}\text{ s}^{-1}$, respectively, at the PCM/B3LYP/6-31+G**//B3LYP/6-31G* level of theory [127,139]. At the same level of theory, the calculated thermodynamic data in aqueous phase also show a more facile addition of $HO_2\cdot$ to DMPO compared with $O_2^{\bullet-}$ with G_{rxn} of -4.6 and 11.9 kcal/mol , respectively [139].

Three possible mechanisms for the DMPO-OOH formation have been proposed (Figure 12). At neutral pH, the addition of $O_2^{\bullet-}$ to DMPO in aqueous solution at pH 7.2 is thermodynamically endoergic ($G_{298K} = 11.9\text{ kcal/mol}$) with an experimental rate constant of $1.3 \times 10^{-3}\text{ M}^{-1}\text{ s}^{-1}$ (Mechanism A) [127]. While the established pK_a for $O_2^{\bullet-}$ is 4.8, the pK_a for DMPO was unknown. The pK_a of the conjugate acid of DMPO was determined to be 6.0 using potentiometric, spectrophotometric, ^1H - and ^{13}C -NMR, as well as computational methods. An alternative mechanism for the spin trapping of $O_2^{\bullet-}$ in mildly acidic pH was, therefore, proposed [140], which indicates that in slightly acidic medium, DMPO can be protonated first (Mechanism B) and can compete with the alternate mechanism where protonation of $O_2^{\bullet-}$ leads to the addition of $HO_2\cdot$ to DMPO (Mechanism C), which is more favorable than the addition of $O_2^{\bullet-}$ (Figure 12). A tenfold increase in the charge density of C-2 was observed upon protonation of the nitronyl-O, therefore, increasing the electrophilicity of the nitron towards $O_2^{\bullet-}$ [140]. Reactivity of DMPO in mildly acidic pH (5.0–7.0) (Mechanism C) can have biological relevance. Mild acidity is characteristic of acidosis and has been observed in hypoxic systems (e.g., ischemic and cancer cells). Since acidosis plays a critical role in the initiation of brain [141,142] or heart damage [143,144] during ischemia, and that production of $O_2^{\bullet-}$ is ubiquitous during these pathophysiological events, spin trapping of $O_2^{\bullet-}$ by nitrones in mildly acidic environment is therefore relevant.

Reactivity of nitrones to other radicals & nucleophiles

Reactivity with $\text{CO}_2^{\bullet-}$ & $\text{CO}_3^{\bullet-}$

Nitron addition to $\text{CO}_2^{\bullet-}$ and $\text{CO}_3^{\bullet-}$ can minimize the effects of these radicals in causing oxidative damage [145,146]. $\text{CO}_2^{\bullet-}$ is formed in acute sodium formate poisoning [147] and is also generated as a metabolic product of CCl_4 in rat liver microsomes [148,149]. $\text{CO}_2^{\bullet-}$ anion is also a key intermediate in both decarboxylase and oxidase biochemistry and has been detected as an oxalate-derived free radical using spin trapping [150]. The carbonic acid–bicarbonate ion equilibrium plays an important role in maintaining pH in blood plasma [151,152]. It has been shown that bicarbonate anion (HCO_3^-) enhances the peroxidase activity of copper–zinc SOD (SOD1) and that this effect involves $\text{CO}_3^{\bullet-}$ formation as induced by cysteine [153] or H_2O_2 [154]. Moreover, $\text{CO}_3^{\bullet-}$ has been found to be produced from a copper–zinc SOD/ H_2O_2 / HCO_3^- system [155] or as a decomposition product of the reaction of ONOO^- and CO_2 (i.e., ONOCO_2^-) [156]. EPR spin trapping of $\text{CO}_2^{\bullet-}$ and $\text{CO}_3^{\bullet-}$ using DMPO shows formation of C-centered carboxylate (DMPO-CO_2^-) and O-centered carbonate (DMPO-OCO_2^-) adducts. The fate of DMPO-OCO_2^- in solution was computationally and experimentally rationalized, and results show that the major decomposition pathway for DMPO-OCO_2^- in solution is via ring-opening of the pyrrolidine ring with subsequent elimination of nitroxyl ($^3\text{NO}^-$) to form nitrite (NO_2^-) [146].

Reactivity with reactive sulfur species

Sulfite ($\text{SO}_3^{\bullet-}$) is an important reactive intermediate and has been shown to be enzymatically generated from eosinophil peroxidase [157] or xanthine oxidase/ H_2O_2 -catalyzed [158] oxidation of sulfite; therefore, $\text{SO}_3^{\bullet-}$ may be implicated in the initiation of oxidative damage [159,160]. Generation of $\text{SO}_3^{\bullet-}$ [161,162] in the presence of spin traps has been shown to give EPR spectra using DMPO. Conflicting reports still arise into the nature of the sulfite adduct formation; for example, Khramstov and co-workers [110] suggest a nonradical pathway via nucleophilic addition reaction and subsequent oxidation; while Rangelova and Mason proposed direct $\text{SO}_3^{\bullet-}$ addition to DMPO from a one-electron oxidation of HSO_3^- as catalyzed by a horseradish peroxidase/ H_2O_2 system [109,161]. For the nucleophilic addition reaction mechanism (Figure 13), the equilibrium constant for the formation of the product of DEPMPO with S-centered nucleophiles decreases in the following order: sulfite > thioglycolic acid > cysteine > glutathione [163]. Reaction of thiols with nitrones can affect local redox states in biological systems and can have implications in cell-signaling events.

Reactivity with reactive nitrogen species

Nitrones have been used for the detection of RNS [164] and have been shown to trap decomposition products and tertiary radicals formed from ONOO^- [165]. Aside from the nitron reactivity with ONOO^- , nitrones have been shown to react with a variety of inorganic radicals and nonradical nucleophiles such as azidyl radicals [166,167], cyanidyl radical [168] and nitrogen dioxide radical [164]. Nitrones are not reactive to NO; instead, nitronyl nitroxide (although not purely a nitron) [169] and Fe(II)-thiocarbamates have been used as probes for NO detection in a variety of experimental conditions [170,171].

Reactivity with protein radicals

Existence of one-electron oxidized forms of amino acid residues in proteins had been proven, and they play crucial roles in the normal function of an enzyme. Tyrosyl, cysteinyl, glycyl and tryptophanyl radicals have been identified as either important cofactors or involved in turnover by enzyme catalytic action [172]. However, oxidative modification of proteins also accounted for their inactivation. Antioxidants may, therefore, act in either preventing enzyme inactivation via reversing the oxidation state of the active sites; preventing protein unfolding through competitive reaction between the antioxidant and the protein radical for the oxidant; or direct reaction of the antioxidant with the protein radical. Formation of protein radicals specifically through cysteine residues can have significant implications in redox signaling and inflammatory responses, which can have a role in the development of pathophysiological conditions. DMPO had been shown to form adducts with glutathyl, hemoglobin-cysteinyl and hemoglobin-tyrosyl radicals from ONOO⁻-mediated oxidation of oxyhemoglobin [173]. A variety of proteins, as well as DNA radicals, have been shown to react with DMPO to form the macromolecule–DMPO adducts. These adducts were detected using the immune spin-trapping technique [174,175]; for example, DMPO adducts of CPB1 [176], myoglobin [177] and mitochondrial cytochrome C [178] via DMPO binding to the tyrosyl and cysteine residues.

Reactivity with lipids

Antioxidant termination of lipid peroxidation chain reaction processes is important in preserving cellular membrane integrity. Peroxyl radicals of polyunsaturated fatty acids, such as linoleic, arachidonic and linolenic acids, play crucial roles in lipid peroxidation and have been shown to form alkoxyl adducts with DMPO [179,180]. Formation of alkoxyl radical adducts was observed from polyunsaturated fatty acid hydroperoxides in the presence of Fe²⁺ and in intact cells [179]. Nitrones have also been shown to form adducts with the radicals of arachidonic acid, dihomog- γ -linolenic acid or docosahexaenoic acid via cyclooxygenase-mediated radical formation [181,182], metal-catalyzed oxidation of diacylglycerophosphatidylcholines [183] or reactions with soybean lipoxygenase [184].

Decomposition of superoxide adduct

The potential therapeutic property of a nitron does not only rely on its reactivity to radicals and nucleophiles, but the decomposition of the aminoxyl-based adducts formed after spin trapping could also further exhibit therapeutic properties. As mentioned above, tetra-alkyl- β -substituted aminoxyl compounds such as TEMPO and PROXYL have been shown to impart therapeutic properties and have found clinical use. However, their radical-scavenging property *in vivo* may not compete with SOD unless in conditions of extreme oxidation stress, such as in the presence of ionizing radiation. Nevertheless, TEMPO shows SOD mimetic properties, where it catalytically transforms O₂^{•-} to H₂O₂ at physiological pH at rate constants 10⁴–10⁵ M⁻¹ s⁻¹, which is four to five orders of magnitude lower than SOD [185]. SOD was also found to reduce nitroxides to their corresponding hydroxylamine in the presence of thiols [186]. However, the main structural difference between tetraalkyl- β -substituted aminoxyls and that of the adducts formed with cyclic nitrones is the presence of

β -H. The absence of β -H in TEMPO and PROXYL is the basis of the reversibility of their redox reactions (Figure 14).

Using a density functional theory approach, the redox properties of the $O_2^{\bullet-}$ adducts of nitrones were investigated [187]. Unlike TEMPO and PROXYL nitroxides, nitron-radical adducts have β -H that make them susceptible to degradation, hence their redox reactions are not reversible. Figure 15 shows the one-electron oxidation and reduction of $O_2^{\bullet-}$ adducts leading to the formation of various products. The thermodynamically preferred decomposition pathway for the one-electron reduction of DMPO-OOH is via formation of the hydroxylamine and subsequent ring opening to form the aldehyde and elimination of HNO_2 . For the one-electron oxidation of DMPO-OOH, the preferred decomposition is the formation of the hydroxamic acid via nucleophilic addition of water. In addition, the formation of C-nitroso aldehyde was shown to be thermodynamically favorable upon DMPO-OOH oxidation (Figure 15). The redox reactions of $O_2^{\bullet-}$ adduct leads to the formation of NO, H_2O_2 and hydroxamic acid. Hydroxamic acid, for example, is widely employed as an iron chelator and enzyme inhibitor [188-190]. The redox activity of nitrones and their spin adducts, as well as the formation of biologically active byproducts, could play crucial roles in regulating cellular redox states, and may explain the pharmacological activities of nitrones against oxidative stress.

By virtue of the oxidation state of $O_2^{\bullet-}$, it can serve as both a reducing and oxidizing agent leading to the formation of O_2 and peroxide (O_2^{2-}), respectively. Unlike TEMPO or PROXYL, DMPO-OOH does not act as an SOD mimetic and its reaction to $O_2^{\bullet-}$ can lead to decomposition products (Figure 16). Compared with DMPO alone, DMPO-OOH gave higher electron affinity, making the nitroxides more susceptible to reduction than nitrones. The ionization potentials of DMPO and DMPO-OOH are not significantly different, but in general are higher compared with the more stable nitroxides such as TEMPO, PROXYL, DMPO-OH and DMPO-CH₃ adducts, indicating a more facile oxidation for these latter class of nitroxides [187]. In buffer solution, kinetic analysis for the decomposition of various nitron-OOH yields pseudo-first-order rate constants in the range of $0.6\text{--}9.0 \times 10^{-3} \text{ s}^{-1}$ corresponding to half-lives of approximately 1–20 min [191]. The short half-lives of the $O_2^{\bullet-}$ adducts can be accounted for by the fact that the $O_2^{\bullet-}$ self-dismutation, whose rate is in the order of $105 \text{ M}^{-1} \text{ s}^{-1}$, can compete with the nitroxide oxidation by $O_2^{\bullet-}$, whose rate is also in the same order of magnitude [185,192,193]. Base-catalyzed decomposition of DMPO-OOH can also yield C-nitroso aldehydes, which explains the instability of such species in basic medium (Figure 17) [194].

Disproportionation of the radical adduct to yield the nitron and hydroxylamine bearing the radical moiety can have implication for further reaction with ROS. Although this disproportionation to form stable nitron-OOH and hydroxylamine-OOH diamagnetic products seems unlikely for $O_2^{\bullet-}$ adducts due to the lability of the O–O bond; formation of nitron- SO_3^- and hydroxylamine- SO_3^- were stable enough to be observed in solution using NMR [110]. Moreover, trapping of C-centered radicals can also yield stable adducts that can disproportionate to nitron-R and hydroxylamine-R species. The implication of the formation of hydroxylamine and nitron from the spin adduct can further enhance the radical scavenging property of nitrones. For example, the observed rate constant for the reaction of

$O_2^{\bullet-}$ with hydroxylamine to form the nitroxide and H_2O_2 is in the order of $10^3 M^{-1} s^{-1}$ [195] and $10^9 M^{-1} s^{-1}$ for $HO^{\bullet}$ reaction with hydroxylamine [196]. In fact, hydroxylamine had been shown to confer protection in cardiomyocytes against oxidative stress [197].

Nitric oxide production from DMPO-OOH decomposition

One-electron reduction (Figure 15) and base-catalyzed decomposition (Figure 17) of DMPO-OOH are some of the pathways leading to the formation of C-nitroso aldehyde. However, unimolecular decomposition via homolytic O-O bond cleavage is one of the main pathways for DMPO-OOH decomposition, as shown in Figure 18. The unimolecular decomposition of the $O_2^{\bullet-}$ adduct of DMPO, DEPMPO and EMPO was experimentally investigated and shows first-order decay kinetics during the whole course of adduct decomposition [198]. Table 3 [199-201] shows the experimental first-order half-life of $O_2^{\bullet-}$ adduct of various nitrones in aqueous solution. The overall calculated $G_{rxn,aq}$ of the $O_2^{\bullet-}$ adducts of AMPO, EMPO, DEPMPO and DMPO decomposition to their respective C-nitroso aldehydes are exoergic, ranging from -2 to -13 kcal/mol, with DMPO-OOH being the most favorable. Less exoergic $G_{rxn,aq}$ of decomposition were observed for the adducts with electron-withdrawing group substitution at C-5, which qualitatively follows the experimentally observed half-lives with DMPO-OOH having the shortest half-life [202].

Decomposition of $O_2^{\bullet-}$ adducts of DMPO, EMPO and DEPMPO in aqueous solution lead to the formation of NO as detected by EPR spin trapping using Fe(II) *N*-methyl-D-glucamine dithiocarbamate. NO release was observed from the $O_2^{\bullet-}$ adduct formed from hypoxanthine/xanthine oxidase, phorbolmyristate acetate-activated human neutrophils, and DMSO solution of KO_2 (Figure 19). However, NO formation was not observed from the independently generated hydroxyl radical adduct. Formation of NO was also indirectly detected as nitrite (NO_2^-) utilizing the Griess assay. Nitrite concentration increases with increasing $O_2^{\bullet-}$ concentration at constant DMPO concentration, while NO_2^- formation is suppressed at anaerobic conditions [61]. This decomposition chemistry of DMPO-OOH can have implication for controlled delivery of NO through radical scavenging. It can be considered that nitrones are both radical scavenging ROS and NO donors (Figure 20). Most of the NO donor drugs are limited by their stability, controlled delivery and targeting properties [203]. In contrast, nitrones can both scavenge ROS and exhibit controlled release of NO as a consequence [61,202] and are, therefore, more desirable and unique among current NO-donating drugs.

Intracellular compartmentalization properties

The reported partition coefficients for cyclic nitrones ($K_p = [nitron]_{n-octanol}/[nitron]_{water}$) are generally low; that is, $K_p < 0.2$, unlike the PBN-type nitrones that can have K_p of up to 30 [204-206]. Recently, various lipid-soluble spin traps derived from EMPO and DEPMPO have been synthesized [205,206]. One of the major limitations of spin traps is their inability to specifically detect radicals at the site of radical formation. Therefore, conjugating spin traps with substituents that are known to compartmentalize in the membrane, cytosol, extracellular matrix and mitochondria could overcome such limitations and can provide optimal radical scavenging, since radicals could be targeted at the site of their production.

Although nitrones such as DMPO, PBN and NXY-059 have been employed as pharmacological agents, they are limited by their lack of intracellular target specificity.

Cell membrane

Radical-induced oxidative damage to the cell membrane primarily occurs through lipid peroxidation process. Membrane-bound radical generators such as NADPH oxidases [207,208] and uncoupled eNOS [209], as well as exogenously produced ROS or ionizing radiation [210], are potential targets for antioxidant therapy. Since the structural organization of the cell membrane bilayer is comprised mainly of phospholipids and sterols, employing cholesterol and long-chain hydrophobic groups as target ligands for membrane compartmentalization is promising [211]. Figure 21 shows some examples of lipophilic nitrones with conjugation to cholesterol (5-ChEPMPO) [212], cyclic-phosphoryl group (CyDEPMPO) [213], adamantane [214] and intermediate chain length aliphatic hydrocarbons, BBPO [215], have been previously synthesized but their biological activity has not been explored.

Cytosol—ROS-producing cytosolic enzymes as mediated by CYP450 [216,217] and non-P450 enzymes, such as aldehyde oxidase [218,219] and xanthine oxidase [98,220], have been implicated in pathological conditions, such as in I/R injury, and play an important role in the biotransformation of drugs and xenobiotic [221-223]. Some of the NO synthase (NOS) isoforms are also found mainly in the cytosol and catalyze NO (or $O_2^{\bullet-}$) production [224,225]. Esterification is the most common method employed in the delivery of probes or drugs inside the cell [226]. Rosen *et al.* employed the use of acetoxymethyl ester-derivatized nitroxides and had shown high intracellular retention in Jurkat lymphocytes due to efficient hydrolysis of the ester by the cytosolic esterases [227,228]. Several ester derivatives of nitrones have also been synthesized. Examples of esterified nitrones that can potentially compartmentalize intracellularly are DEEPN [204], DEPO [229], EMAPO [132] and BMPO [230] (Figure 22).

Mitochondria—Mitochondrial respiration accounts for approximately 90% of the oxygen consumed in the cell and produces high levels of ROS, and has been implicated in a variety of pathophysiological conditions [231-233]. The mitochondrial respiratory chain is a major source of $O_2^{\bullet-}$ and is central to activating apoptosis. Oxidative damage due to unregulated production of $O_2^{\bullet-}$ can lead to cell death. Antioxidants have been successfully delivered to the mitochondrion through conjugation with a lipophilic triphenylphosphonium cation (TPP) [234-236]. Mitochondrial uptake of TPP occurs through permeation in the lipid bilayers and accumulation within the mitochondria by several hundred-fold due to the large mitochondrial membrane potential of -150 to -170 mV versus the plasma membrane potential (-30 to -60 mV) [237]. Studies show that TPP can also concentrate from the extracellular fluid into isolated cells from which they further concentrate within the mitochondria by approximately 90%. Selective target delivery to the mitochondria in principle can be achieved through conjugation of TPP with spin traps such as in the case of MitoPBN [237], MitoDEPMPO [238] and MitoSpin [239], as shown in Figure 23. Moreover, some positively charged *N*-aryl [240] and *N*-alkyl [241,242] pyridinium nitrones have also been synthesized to investigate $O_2^{\bullet-}$ production from mitochondria, and were

shown to successfully trap $O_2^{\bullet-}$ produced from intact mitochondria, albeit not from intact cells.

Extracellular & amphiphilic nitrones—Application of spin traps that can exclusively accumulate outside the cell is important for the investigation of free radicals produced by exogenous agents such as ionizing radiation, particulates, cell culture medium, or through diffusion of H_2O_2 (and, hence, $HO^{\bullet}$ via Fenton-type reaction) to the extracellular matrix [243,244]. Due to the high impermeability of lipid bilayers to polar molecules [245], substituents that contain terminal ionic groups such as carboxylates can be potential extracellular spin traps, such as in the case of CMPO (Figure 24), although its ability to trap $O_2^{\bullet-}$ is limited [246], perhaps due to the repulsive effect of the carboxylate group.

Amphiphilic nitrones, composed of a hydrophilic polar head and a lipophilic group, were shown to efficiently inhibit oxidative stress-mediated damages with a high potency [247-249]. Amphiphilic compounds possessing both hydrophilic and lipophilic groups may exhibit improved cellular permeability [247,250,251]. The hydrophilic polar head of the amphiphiles provides water solubility while the hydrophobic tail ensures sufficient lipophilicity to pass through cell membranes. Durand *et al.* reported the synthesis of novel amphiphilic amide nitrones, comprising a lactobionic acid based polar head group and an alkyl chain, both linked via an amide bond to the *N-tert*-butyl group and the phenyl ring of the PBN moiety (LPBNAH and LPBNH15) were found to improve the mitochondrial bioenergetics and confer protection against dopamine-induced mitochondrial dysfunction [252]. Glycosylated amphiphilic linear and cyclic nitrones, (FAPBN and FAMPO) [247] and lectin directed [253] ones have also been synthesized, however their application for the detection of $O_2^{\bullet-}$ in cells has yet to be evaluated. Co-conjugation of long chain hydrocarbons to β -cyclodextrin nitron conjugate (CDNMPO) forming C_{12} CDMPO [132] also showed amphiphilic property (Figure 24).

Peptidic nitrones—Previously, a PBN-type nitron with an iodoacetamide group was recently synthesized by Liu *et al.* and was used to conjugate with GSH (to form GS-PBN or GS-PPN) (Figure 25) or bovine serum albumin (BSA) [254,255]. The PBN-peptide conjugate was successfully used to trap C-centered radicals in water and $O_2^{\bullet-}$ in the case of GS-PPN. The synthesis of the biotinylated analogue of DMPO (Bio-SS-DMPO) could allow facile conjugation of targeted peptidic ligands to nitrones [256].

Biconjugation—Through bi-functionalization of the nitrones, one would be able to integrate most of the desired spin-trapping properties in one molecular design such as high reactivity to $O_2^{\bullet-}$, improved bioavailability and target specificity. Only a limited number of disubstituted nitrones, however, have been synthesized over the past years, such as C-5 diesterified nitron (DECPO) [257], *N*-hydroxysuccinimide-, biotin-, alkylphosphonium-, Me- β -cyclodextrin-conjugated DEPMPO at C-4 (as NHS-DEPMPO, biotin-DEPMPO, mito-DEPMPO and CD-DEPMPO, respectively) [238,258], amphiphilic PBN derivative (LPBNAF) [259] and the C-5 disubstituted cyclic nitron with a long-chain hydrocarbon and β -cyclodextrin (C_{12} CDMPO) (Figure 24) [132]. There are three popular linker groups that have been employed for molecular tethering of cyclic nitrones, that is, ester, amide and phosphoryl groups. The main advantage of these groups is that due to their electron-

withdrawing properties, they can increase the electrophilic character of C-2 through inductive effect and, in the case of amide substitution, α -effect can facilitate $O_2^{\bullet-}$ addition to nitrones. The biconjugation of the nitron, such as in the case of C_{12} CDMPO, can provide opportunities for a nitron design that includes target specificity to cellular compartments.

Recently, it has been predicted through a computational approach the unusually high exoergic $G_{298K,aq}$'s for $O_2^{\bullet-}$ adduct formation for (2*S*,4*S*)-2-methyl-2,4-bis(methylcarbamoyl)-1-pyrroline *N*-oxide (Figure 26) and HOO adduct formation for (2*R*,3*R*)-2-(dimethoxyphosphoryl)-3-(ethoxycarbonyl)-1-pyrroline *N*-oxide with $G_{298K,aq} = -3.3$ and -9.4 kcal/mol, respectively. These energetics are the most exoergic $G_{298K,aq}$ observed thus far for any nitrones at the level of theory employed in this study [260].

Stability, cytotoxicity & cytoprotective properties

Nitron stability

The reported reduction potentials for nitrones are mostly >-2.0 V [261] while GSH and ascorbate have standard reduction potentials of $E^{\circ}_{red} = 0.92$ V and 0.28 V [118], respectively. Therefore, nitrones in the presence of ascorbate and GSH are stable. The oxidation potential of DMPO, for example, ($E^{\circ} O_x = 1.63$ V) [262] is significantly higher than any of those generated in biological systems in which the only conceivable oxidants are the radicals themselves [109]. In general, nitrones with electron-withdrawing group substitution at the C-5 position result in higher calculated electron affinities and ionization potentials, making these nitrones more susceptible to reduction, but they are more difficult to oxidize compared with DMPO. Reduction of nitrones yielded elongated N-C₂ and N-O bonds but shorter C₅-N bonds, while their oxidation only results in a slight elongation of the N-C₂ bond. Figure 27 shows the mesomeric forms for the oxidized and reduced nitrones showing electron delocalization on the nitronyl-N and -O for the reduction and oxidation forms, respectively [187].

Cytotoxicity

Nitron toxicity on bovine aortic endothelial cells was assessed on various spin traps and nitroso compounds after 24 h of incubation. The lowest toxicity was observed for DMPO ($IC_{50} \sim 140$ mM), but toxicity was highest for the nitroso compounds ($IC_{50} \sim 0.1$ mM) [263]. The more lipophilic nitron, PBN, gave higher toxicity ($IC_{50} \sim 9$ mM) than DMPO. In a separate study, cytotoxicity of DMPO, CMPO, EMPO, BMPO and DEPMPO were compared using Chinese hamster ovary cells and results indicate negligible toxicity within the concentration range of 2.5–50 mM of spin trap concentrations, except for BMPO, which gave significant toxicity at 50 mM. Effect of the spin traps on the number of colonies formed in Chinese hamster ovary cells and 9L-tumor cells was found to be cell-type dependent [264]. Cytotoxicity of various derivatives of EMPO on different carcinoma cell lines also show BMPO to be the most toxic ($IC_{50} \sim 5$ – 6 mM) for all cell lines [265], with DEPMPO and *i*-PrMPO as the least toxic ($IC_{50} \sim 100$ – 300 mM), but are cell-line dependent. Conjugation of an amphiphilic carrier to PBN and DMPO to form FAPBN and FAMPO, respectively, only affects FAMPO toxicity but not FAPBN. FAMPO showed 20% and 50% decrease in cell viability at 0.5 and 1 mM, respectively, while the carrier alone gave cell

toxicity of 5–25% at 0.025–1.0 mM [247]. These results indicate that cellular permeability plays an important role on nitrone toxicity.

Cytoprotective properties

The cytoprotective property of nitrones is dependent on nitrone cellular permeability and oxidant compartmentalization properties. Cytoprotection of fluorinated amphiphilic carrier (FA) conjugates of cyclic (FAMPO) and linear (FAPBN) nitrones against hydrogen peroxide (H_2O_2), ONOO^- (via SIN-1) and 4-hydroxynonenal-induced cell death using BAEC was investigated [247]. FAPBN gave the most robust protection against H_2O_2 while FAMPO was found to be most protective against SIN-1, and none of the spin traps were protective against 4-hydroxynonenal. HPLC analyses revealed that FAMPO and FAPBN localize extra- and intra-cellularly, respectively, only during the first 2 h of incubation. It is expected that H_2O_2 ($\text{pK}_a > 15$) can diffuse inside the cell while ONOOH ($\text{pK}_a = 6.8$) is mostly present as anion in neutral pH, and therefore should be extracellular. Our unpublished results show that $\text{C}_{12}\text{CDMPO}$ was relatively more protective than the nonconjugated cyclodextrin and β -CD-nitron conjugate, CDNMPO [Villamena F, Unpublished data]. However, the nontarget-specific nitrones, AMPO, a carbamoyl-substituted nitron and DMPO gave the highest protection compared with $\text{C}_{12}\text{CDMPO}$, indicating the varying cellular localization of the nitrones affects their cytoprotective properties.

Therapeutic applications of nitrones

Since the seminal work of Novelli *et al.* [45,266], nitron spin traps have been widely used as protective agents in several biological models, such as I/R injury to the heart [53,267,268], brain [269,270] and lung [271], stroke [47,55,272,273] neurodegenerative diseases [274–276], cancer [54,56,277,278], ageing [248,279], visual impairment [49,280] and loss of hearing function [281–283]. In two review articles published by Floyd *et al.* [51,55] the protective properties of the PBN nitrones against stroke, neurodegenerative disorders, hearing impairment, aging and cancer have been elaborately discussed. In this section, we have included only the most recent developments in nitron therapeutics for both PBN and DMPO against ROS-related disorders, with special emphasis on their mechanism of action.

Cardioprotection

The heart is one of the major organs affected by uncontrolled ROS production. Recent evidence suggests that oxidative stress is a common denominator in many aspects of cardiovascular diseases. Mitochondrial dysfunction, which is characterized by inactivation of the ETC, is an important source of ROS during ischemia [107,284]. There are several reports of ROS from mitochondria [285], NADPH oxidases [286], xanthine oxidase [287] and NOS [288,289] being key mediators of cardiac damage during I/R injury. A reperfusion-associated burst of $\text{O}_2^{\bullet-}$ generation has been shown to occur when isolated hearts are subjected to ischemia and reperfusion [104,107]. The radical-scavenging properties of nitrones have enhanced their applications as cardioprotective agents in the last two decades due to the critical roles free radicals play in the pathogenesis of I/R-induced myocardial dysfunction. In the early 1990s, there were reports of applications of PBN and DMPO

against cardiac injuries [290-293]. DMPO was shown to confer protection against I/R-induced oxidative damage in isolated rat and guinea pig hearts. Recently, Tanguy *et al.* reported that LPNAH, an amphiphilic derivative of PBN, exhibits cardioprotective properties in isolated rat hearts [249]. Aside from the conventional nitrones, PBN and DMPO, a novel second-generation azulenyl nitron known as stilbazulenyl nitron was also reported to confer protection against myocardial I/R injury [267]. While the mechanism of cardioprotective action for nitrones is not well understood, it is becoming apparent there is more to the radical-scavenging property of nitrones to explain their cardioprotective properties. Zuo *et al.* showed that DMPO confers protection against cardiac I/R injury by salvaging the mitochondrial ETC complexes [53]. This report adds a new insight to the mechanism of cardio-protection by nitrones. It is well established that inactivation of the mitochondrial ETC is an important event for ROS generation [285,294]. It was observed that DMPO treatment reduces ROS formation, improves the recovery of left ventricular function and coronary flow in the post-ischemic heart models and decreases the infarct size. The infarct size was found to be decreased significantly from $23.0 \pm 3.0\%$ in the untreated control hearts to $14.4 \pm 2.6\%$ in those treated with 1 mM DMPO (Figure 28). The enzymatic activities of the mitochondrial ETC complexes were also found to be recovered in DMPO-treated hearts. Upregulation of the mitochondrial proteins associated with ETC, such as FMN-binding subunit of complex I, FAD-binding subunit of complex II, and subunits I and Vb of complex IV was observed in post-ischemic hearts treated with DMPO (Figure 29). eNOS-derived NO is known to play an important role in mitochondrial biogenesis [295,296], but it is not very clear whether DMPO itself modulates eNOS activity or if NO is originating as a metabolite product from decomposition of the nitron [61]. Hence, future studies are needed to further characterize the precise molecular mechanisms of DMPO-induced myocardial protection.

Retinal protection

Retinal dystrophies in humans comprises a group of inherited ocular disorders characterized by the loss of visual functions including night blindness, narrowing of the visual field, reduced central vision and increasing sensitivity to glare. Exposure to bright light enhances the progression and severity of the age-related macular degeneration and some forms of retinitis pigmentosa [297,298], usually observed in older adults resulting in blindness and visual impairment. Apoptosis of photoreceptors and retinal pigment epithelial cells due to acute light exposure has been reported as the key events that lead to age-related macular degeneration and retinitis pigmentosa [299,300]. Oxidative stress is known to be an early event in light-induced retinal damage and has been detected within minutes of light exposure [301]. Generation of ROS due to the retinal exposure to intense light has been implicated as a key mediator of photoreceptor death in multiple ocular disorders [302-304]. It has also been reported that exposure of the cultured rod cells to blue light leads to ROS generation via impairment of the mitochondrial ETC [305], whereas the cultured retinal ganglion cells were reported to exhibit mitochondrial-mediated oxidation and apoptosis as a consequence of light-induced oxidative stress [306].

Various natural and synthetic antioxidants, such as coenzyme Q [307], melatonin [308], sulforaphane [309], α -tocopherol [310], CAT [311] and antioxidant gene therapy [312] have

been reported to either directly or indirectly prevent the retinal degeneration. Due to its radicalscavenging property, PBN was administered to prevent the light-induced ocular dysfunction. Therapeutic application of this spin trap against light-induced retinal damage was first reported by Ranchon *et al.* [313]. According to their study, direct injection of PBN into retina of the albino rats confers protection against light-induced retinal degeneration. Over the past decade, several studies have been performed to elucidate the exact mechanism of protection by PBN against light-induced visual damage. Intraperitoneal administration of PBN (50 mg/kg) to the rats 30 min prior to light exposure (2700-lux intensity of fluorescent light) was found to inhibit the induction of apoptosis in the treated animals compared with control rats [314].

Activation of the transcription factor AP-1, which mainly consists of a c-Fos/junD heterodimer [300,315], is known to be a crucial event in light-induced apoptosis of the retinal cells [314,315]. In the c-Fos-depleted mice (*c-fos*^{-/-}), the normal retinal function and morphology was found to be similar to that of the wild-type, but the *c-fos*^{-/-} mice were found to be highly resistant to light damage compared with the wildtype mice [316]. Furthermore, it was reported that deletion of JunD or c-Jun has no effect on retinal protection [317,318], which confirms the importance of c-Fos in AP-1-mediated apoptosis of the retinal cells. Tomita *et al.* reported that pretreatment of Sprague-Dawley rats with PBN significantly inhibited both c-Fos expression and AP-1 activation [314]. But the mechanism by which AP-1/c-Fos activation is inhibited by PBN is not very well understood. It has been reported that expression of c-Fos in mouse retina depends on the light–dark cycle (visual cycle) [319]. In *Rpe65*^{-/-} mice depleted for Rpe65 (an important enzyme participating in the visual cycle), c-Fos expression was significantly decreased compared with the wild-type [320]. The gene *rpe65* codes for a 65 kD enzyme, which catalyzes the hydrolysisisomerization of all-*trans*-retinyl esters to 11-*cis*-retinol, an important step of the visual cycle [321-323]. The 11-*cis*-retinol after being oxidized to 11-*cis*-retinal binds covalently to the protein opsin to form the visual pigment rhodopsin [323]. Thus, 11-*cis*-retinal acts as a chromophore of rhodopsin, and since rhodopsin bleaching is reported as the ‘trigger’ for retinal light damage [324,325], prevention of rhodopsin regeneration within the visual cycle may lead to the protection from light-induced retinal damage. This hypothesis was strongly supported by the knockout animal studies, where it was shown that the *Rho*^{-/-} (depleted for rhodopsin) and *Rpe65*^{-/-} mice had acquired resistance to light damage [320]. Mandal *et al.* reported that the pretreatment, but not the post-treatment, of Albino Sprague-Dawley rats with PBN resulted in the inhibition of light-induced retinal damage, indicating that PBN might interfere with the initial events that trigger the light-induced damage [49]. Interestingly, they observed that the isomerohydrolase activity of Rpe65 is inhibited by PBN and this is accompanied by the suppression of rhodopsin regeneration [49]. This report adds up a new insight in explaining the molecular mechanism of PBN-induced ocular protection. Since it is known that a full visual cycle is required for c-Fos expression [319], inhibition of the visual cycle by PBN may be the mechanism by which c-Fos expression is modulated in PBN-treated retinal cells.

Photobleaching of the visual pigment rhodopsin is the key event that triggers light-induced damage [323]. The rate of rhodopsin regeneration is an important factor in modulating the light sensitivity of the retina. Rapid regeneration of rhodopsin after photobleaching increases

the retinal susceptibility to light exposure, whereas reversing this process enhances the resistance of the photoreceptors to light-induced damage. Although it was reported that PBN treatment resulted in the significant inhibition of the visual cycle enzyme Rpe65, the mechanism of inhibition required further discussion. One hypothesis put forward in the same article stated that the isomerohydrolase reaction catalyzed by Rpe65 involved the formation of an intermediate retinoid radical cation and PBN might trap this radical to inhibit the progression of the reaction [49]. It has been reported that PBN can form stable adducts with the carotenoid radicals [326] and, furthermore, it was observed that PBN did not bind to free Rpe65 enzyme but rather binds to the enzyme–substrate complex to inhibit Rpe65 activity in an uncompetitive fashion [49]. This observation strengthens the idea that PBN may bind to the retinoid radical intermediate that forms a complex with the enzyme at its active site. Due to its hydrophobicity, PBN can readily enter the active site of the enzyme and can trap the retinoid radical to inhibit the reaction. S-PBN, a relatively hydrophilic derivative of PBN, is reported to be unsuccessful in inhibiting Rpe65 activity, and simultaneously does not confer protection to retina against light-induced damage. In one study, Poliakov *et al.* had reported that more hydrophilic spin traps, such as DMPO, S-PBN, α -(4-pyridyl 1-oxide)-*N*-tert-butyl nitron and NXY059, did not inhibit Rpe65 activity up to 400 μ M [327], which clearly suggests the SAR behind the antagonistic roles of nitrones against light-induced retinal damage. In spite of the progress made in the elucidation of nitron protection against ocular degeneration, the mechanism of action of nitrones is still not well understood and warrants further investigation.

Anticancer properties—Based on the fact that ROS play a crucial role in carcinogenesis, PBN and its derivatives, such as 4-OHPBN or 3-OHPBN and OKN-007, have been administered against several carcinoma models [58,277,328-330]. In reviews by Floyd *et al.*, the anticancer role of PBN and PBN-derived compounds against hepatocellular carcinoma and glioma models had been elaborately discussed [54,55]. In this article, we have tried to focus on the recent developments of nitron therapeutics in anticancer research and also highlight the mechanisms behind the anti-tumorigenic properties of nitrones, although the exact mode of nitron action is still far from being understood.

The anticancer property of PBN nitrones was first reported by Nakae *et al.* on choline-deficient L-amino acid deficient (CDAA) rats with hepatocarcinoma [331]. Recently, anti-tumorigenic properties of PBN and OKN-007 were further investigated in glioblastomas, which represent the most common form of adult brain tumors. It was reported that application of PBN compounds inhibited the rate and extent of tumor progression and angiogenesis in C6 rat glioma models [58,328]. PBN was administered to the rats in drinking water (75 mg/kg/day) either 5 days prior to implantation with C6 glioma cells (pretreatment group) or approximately 14 days after the glioma implantation (post-treatment groups). Parameters associated with tumor progression and angiogenesis were assessed by MRI and magnetic resonance angiography, respectively. It was observed that administration of PBN resulted in the significant inhibition of tumor growth and progression in both pre- and post-treatment conditions, while the survival of the implanted rats had increased considerably (up to 40%) in PBN-treated groups [328]. The PBN-derivative OKN-007 was also found to induce tumor regression and enhance the survival of C6 glioma rats when

administered in post-tumor stage. Treatment with OKN-007 resulted in the drastic reduction of tumor volume (~threefold), a decrease in apparent diffusion coefficients (~20%) and a simultaneous increase in the tissue perforation rates compared with the untreated rats [58].

After the successful application of PBN nitrones against liver and brain cancer models, they were challenged against colon cancers. The anticancer potential of nitrones was investigated in APC^{min/+} mice models for colorectal cancer [60]. APC is a multifunctional protein that can trigger the activation of β -catenin and induction of WNT signaling [332,333]. In APC^{min/+} mice, the adenomas are developed in the early stages of infancy and they are subjected to death at 16–20 weeks of tumor progression due to intestinal hemorrhage [334]. When these tumor-bearing mice were administered with PBN in drinking water (100 mg/kg/day), a significant reduction in the tumor volume and associated intestinal adenomas were observed [60].

Although PBN-derived nitrones were found to be effective against various tumor models, the mechanism by which they induce tumor regression is not very clear. Unlike the popularly used anticancer drugs – curcumin, resveratrol, cisplatin and doxorubicin, to name a few – nitrones do not possess cytotoxic potential against cancer cells. It is reported that PBN had no detrimental effect on cancer cells [60]. But the anti-inflammatory properties of nitrones may be the key to their effectiveness against tumor progression as inflammation and cancer development are intertwined. There is a long-standing relationship between cancer and inflammation, and the modulators of inflammation, such as NF- κ B, Cox-2 and iNOS, are known to play important roles in carcinogenesis [335-337]. It has been reported that PBN treatment resulted in downregulation of the expression of these inflammatory genes in liver carcinogenesis [331] and macrophages [338]. NO plays an important role in tumor growth and angiogenesis, and the hepatocytes isolated from CDAA rats were found to produce high levels of NO compared with those isolated from the rats fed with normal diet. Similarly, the bile flowing in the liver of the CDAA rat showed enhanced NO production compared with normal rats, confirming the importance of NO in liver carcinogenesis [54]. The cyclic nitrone, DMPO, was found to inhibit LPS-induced oxidative and inflammatory stresses in cultured macrophages. DMPO protected cells from LPS-induced toxicity via downregulation of iNOS expression after 24 h of nitrone incubation. Early genes were also investigated within 16–60 min and showed DMPO inhibition of MAPKs, Akt and I κ B α phosphorylation, and reduced the NF- κ B p65 translocation [339].

Beside the anti-inflammatory activity of nitrones, PBN compounds were also reported to modulate tumor metabolism in glioma models [58]. In a very recent report by He *et al.* it was shown that treatment of C6 glioma rats by PBN and OKN-007 resulted in the alteration of the levels of metabolites associated with brain cancer [58]. MRI results revealed that levels of the major metabolites such as choline, creatine, *N*-acetyl aspartate and lipids (lip 1.3 and lip 0.9) were affected by nitrone treatment throughout the course of tumor progression. Thus, the levels of *N*-acetyl aspartate and creatine were found to decrease in the untreated C6 rats, but in the presence of PBN and OKN-007 their levels had increased significantly. Alterations in lipid levels have been previously demonstrated to be a marker of tumor malignancy and indication of response to treatment [340,341]. When C6 rats were treated with nitrones, drastic alterations in lipid levels were observed at different phases of

tumor progression. Thus, it may be concluded that nitrones can induce tumor regression by inhibiting the onset of inflammation and also by modulating tumor metabolism.

Conclusion

By exploiting the intermolecular and intramolecular hydrogen bonding interaction from an amide linker group and substituents with the nitron moiety and $O_2^{\bullet-}$, $O_2^{\bullet-}$ addition reaction to nitrones can be greatly facilitated. For targeting $O_2^{\bullet-}$, employing anion recognition using synthetic receptors, which has been gaining attention in the field of host-guest chemistry due to their potential biological and environmental applications [342], could be a very promising strategy in increasing $O_2^{\bullet-}$ reactivity to nitrones. Synthetic anion receptors employ hydrogen bond donors using amide, urea, thiourea, sulfonamides or hydroxyl groups mimicking naturally occurring anion-binding sites. Results (both computational and experimental) indicate extraordinary enhancement of $O_2^{\bullet-}$ addition reaction to nitron via conjugation of the nitron to calix[4]pyrrole and protection of the spin adduct from $O_2^{\bullet-}$ itself, thereby significantly increasing the adduct $t_{1/2}$ [133]. Synthesis of nitron-anion-receptor conjugates can potentially extraordinarily enhance the rate constants for $O_2^{\bullet-}$ addition to nitrones, increase biostability of the nitrones and adducts by making them less susceptible to bioreduction/oxidation, and improve cellular permeability through biconjugation to target specific groups.

The mechanism by which nitrones impart their antioxidant properties in cells or animal models is not clear cut, where their spin-trapping property is not solely responsible for their therapeutic property. However, what is clear is that nitrones can act in a variety of pathways that can alter the redox state of the system via ROS/RNS scavenging and NO donation – all of which have significant implications in the control of signaling transduction and gene induction. The lack of multifunctional antioxidants that can ameliorate cardiovascular disease is a key factor limiting the application of antioxidants as therapeutic agents. Synthetic antioxidants commonly function as direct radical scavengers (e.g., SOD mimetics, mitochondria-targeted nitroxides, quinones and vitamin E) or indirectly by bolstering antioxidant defense mechanisms (e.g., ebselen derivatives and α LA), but nitrones offer promising therapeutic potential by scavenging ROS/NOS, increasing NO bioavailability, bolstering antioxidant defenses and by inhibiting pro-apoptotic pathways. Nitron therapeutics as applied to the treatment of diseases, with the goal of ameliorating, reversing or preventing the effect of oxidative injury, have yet to be fully explored due to lack of innovative nitron designs that can increase bioavailability and target the specific subcellular effector compartments. Given the number and the variety of antioxidant-based therapeutic strategies, few antioxidants have found clinical application, such as *N*-acetylcysteine, α -LA and some flavonoids [343]. Nitrones offer potential as therapeutic agents due to the rich chemistries and biological activities they impart. However, the unsuccessful application of NXY-059 to clinical use, as discussed by Firuzi *et al.* [343] showed a need for developing antioxidants that are more disease-specific, organelle- or cellular-targeted, and bioavailable.

Nitron therapeutics can be mechanism specific. For example, in the pharmacology of cardiovascular disease affecting contractile function of the heart, uncoupling of the mitochondrial ETC and NOSs or ROS/RNS-mediated alteration in intracellular calcium

handling, are reasonable targets. Compounds that can target these mechanisms all at once by preventing, minimizing or ameliorating the effects of ROS can be a powerful therapeutic strategy. ROS generation can increase under conditions of hyperoxia and post-I/R and can cause mitochondrial dysfunction via inactivation of the ETC complexes. Therefore, therapeutic drugs that are targeted to the mitochondria may provide better pharmacological effects against I/R injury. Moreover, abnormalities in calcium handling have been implicated in many forms of cardiac disease. An increase in intracellular calcium can result in further release of calcium from the sarcoplasmic reticulum (SR) via the ryanodine receptor, and this increases free intracellular calcium concentration by several-fold. Evidence is also mounting that neuronal NOS enhances contractile function through regulation of SR calcium cycling [344]. Altered regulation of $O_2^{\bullet-}$ and NO occurs in various cardiomyopathies (i.e., I/R injury and heart failure), making NOS an ideal target for therapeutic study. I/R is characterized by upregulated overproduction $O_2^{\bullet-}$ and, therefore, NO bioavailability can be compromised due to the high rate of $O_2^{\bullet-}$ reaction with NO approaching diffusion controlled limit to form $ONOO^-$. In conditions of oxidative stress, eNOS can switch from producing NO to $O_2^{\bullet-}$, a process called eNOS uncoupling. This uncoupling is presumed to be primarily caused by oxidation of the cofactor BH_4 by $ONOO^-$ [345]. An increase in ROS, such as $O_2^{\bullet-}$, together with decreased NO bioavailability contribute to endothelial dysfunction, which can lead to cardiovascular disease. Therefore, therapeutic agents that can target cytosolic matrix and affect kinase-mediated phosphorylation processes in the cell may be able to upregulate eNOS. Nitrones being both $O_2^{\bullet-}$ scavengers and NO donors [61] may exhibit pharmacological activity against cardiac mechanical dysfunction caused by I/R injury. Recently, lipophilic NO-donor and lipophilic antioxidants, when introduced as hybrid molecules, not as a mixture, can exhibit cardiac protection from I/R through significant reduction of infarct size with improved recovery of cardiac function [346]. Moreover, magnesium lithospermate B has been shown to protect endothelium from hyperglycemia-induced dysfunction via eNOS phosphorylation and induction of phase II enzymes by Nrf-2 nuclear translocation, while α -LA was claimed to be unable to cause these effects [347]. Recently, our laboratory had shown that nitrones can inhibit ROS-induced apoptosis in endothelial cells via increased phase II enzyme activity through Nrf-2 nuclear translocation and suppression of mitochondrial-dependent pro-apoptotic signaling [348].

Future perspective

Our hypothesis centers on how nitrones can regulate *S*-glutathionylation. *S*-glutathionylation [349] has been gaining attention as an important mechanism in the induction of signal-transduction processes as regulated by the cellular redox status. Glutathionylation is a post-translational oxidative protein modification that involves cysteine coupling with the tripeptide glutathione, an abundant low-molecular-weight molecule. It has been shown that glutathionylation is involved in modulating Nrf-2 transcription and in the induction of antioxidant genes expression. Moreover, glutathionylation of cysteine proteins under oxidative stress conditions has been implicated in altered Ca^{2+} signaling [350,351], mitochondrial damage [352] and eNOS uncoupling [353], the three major biochemical events that have the most profound effect on I/R. Therefore, determination of the main location of oxidant production relevant to glutathionylation is important. We have

preliminary evidence showing that DMPO and some of its analogues salvage mitochondrial ETC dysfunction during I/R, reverse eNOS uncoupling and improve Ca^{2+} handling, which could explain the cardioprotective property of DMPO in isolated rat heart during I/R [53]. Considering that eNOS is mostly localized near the cell membrane and that mitochondria and SR are mostly cytosolic, the use of nitrones that can specifically target these compartments can provide opportunities to pinpoint the most effective cellular sites for the prevention of *S*-glutathionylation since nitrones such as DMPO and DEPMPO have been shown to reversibly add to glutathionyl radicals [354,355]. By identifying which targeted cellular event/s contributes the greatest to I/R injury, and which target-specific nitron (or combinations thereof) will exhibit the most robust protection, can give valuable insights into the mechanisms of nitron protection. Also, by correlating the degree of *S*-glutathionylation with the ability of spin trap to reverse eNOS uncoupling, salvage mitochondrial dysfunction and improve contractility, will be helpful in determining the main cause of oxidative stress.

Successes in nitron therapeutics can perhaps be accomplished by also focusing on the organelle specificity of drug delivery. Targeting organelles where mechanisms of oxidative stress mentioned above mostly occur can be an effective strategy in minimizing oxidative stress. For example, Golgi apparatus [356] have been gaining attention as an important organelle implicated in oxidative stress since it is a vital organelle responsible for protein misfolding, resulting in many pathophysiological conditions such as neurodegeneration and cardiovascular diseases [357]. Endoplasmic reticulum (ER) stress has also been implicated in various pathophysiological conditions. The ER is an organelle responsible for protein folding, calcium homeostasis and lipid synthesis, and deviation from its normal function can lead to the accumulation of unfolded or incorrectly folded proteins resulting in ROS production [358,359]. The activity of eNOS is highly regulated by the post-translational myristoylation and palmitoylation of the enzyme, which results in its translocation from Golgi to the cholesterol-rich domains of the plasma membrane including the caveolae and lipid rafts [360]. Therefore, targeting post-translational regulation of NOS activity in specific organelles, such as the plasma membrane, SR/ER or Golgi, may salvage or reverse eNOS uncoupling where it is most susceptible. Conjugating Golgi-specific lipids such as C5-ceramide and C6-sphingomyelin or ER-targeting carbocyanine moieties to spin traps will facilitate their better compartmentalization in the cellular milieu. Thus, the application of these novel conjugated nitrones to elucidate mechanisms of NOS uncoupling in each of the subcellular compartments may enhance the scope of nitron therapeutics in the treatment of ROS-related disorders.

Nitrones can be applied as potential therapeutic agents in the treatment of chronic metabolic disorders comprised of inter-related pathophysiological conditions such as hypertension, diabetes, chronic kidney disease and hypercholesterolemia. Nitrones have potential in modulating insulin signaling and resistance by minimizing the effects of ER stress, which play a crucial role in the regulation of several metabolic pathways that can lead to chronic metabolic disorders. Perhaps one effective therapeutic strategy is a multidrug delivery approach, in which various organelle-specific nitrones can be introduced *in vivo*, which may provide a more effective way of sequestering ROS at different locations simultaneously.

Looking into the future of nitron therapeutics, the diagnostic ability of nitron to detect free radicals can be concurrently exploited and employed as theranostic agents for future applications similar to that of nanoparticles [361], since multiconjugation of the nitron is now possible. Co-conjugation of nitrons with other probes, drugs, delivery vectors and/or stabilizing agents can further enhance nitron theranostic ability. The biomedical values of developing new spin traps include understanding the origin of radical production, toxicology of xenobiotics and antioxidant activity of some compounds, as well as improving the accuracy of radical identification, which could potentially open up new grounds. Looking into the future of nitron therapeutics, the diagnostic ability of nitron to detect free radicals can be concurrently exploited and employed as theranostic agents for future applications similar to that of nanoparticles [361], since multiconjugation of the nitron is now possible. Co-conjugation of nitrons with other probes, drugs, delivery vectors and/or stabilizing agents can further enhance nitron theranostic ability. The biomedical values of developing new spin traps include understanding the origin of radical production, toxicology of xenobiotics and antioxidant activity of some compounds, as well as improving the accuracy of radical identification, which could potentially open up new grounds in spin-trapping applications from cellular level to whole animals. However, this would entail big leaps in the development of spin traps with extraordinary stable spin adducts *in vivo* and the development of spin traps with platforms different to the parent DMPO, coupled with advances in imaging technology either by nuclear medicine, magnetic resonance or optical imaging.

Acknowledgments

This work was funded by a grant from NIH National Heart, Lung and Blood Institute (RO1HL081248).

References

Papers of special note have been highlighted as:

- of interest
- of considerable interest

1. Halliwell, B., Gutteridge, JMC. Free Radicals in Biology and Medicine. 4th Edition. Oxford University Press; NY, USA: 2007.
2. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. *Nature*. 2000; 408(6809):239–247. [PubMed: 11089981]
- 3■. Winterbourn CC. Reconciling the chemistry and biology of reactive oxygen species. *Nat Chem Biol*. 2008; 4(5):278–286. Relationship of the effects of reactive oxygen species (ROS) in biological systems. [PubMed: 18421291]
- 4■. Koppenol WH, Stanbury DM, Bounds PL. Electrode potentials of partially reduced oxygen species, from dioxygen to water. *Free Radic Biol Med*. 2010; 49(3):317–322. Survey of the physicochemical properties of various ROS. [PubMed: 20406682]
5. Martinez MC, Andriantsitohaina R. Reactive nitrogen species: molecular mechanisms and potential significance in health and disease. *Antioxid Redox Signal*. 2009; 11(3):669–702. [PubMed: 19014277]
6. Miller AA, Drummond GR, Sobey CG. Reactive oxygen species in the cerebral circulation: are they all bad? *Antioxid Redox Signal*. 2006; 8(7–8):1113–1120. [PubMed: 16910759]
7. Bindoli A, Fukuto JM, Forman HJ. Thiol chemistry in peroxidase catalysis and redox signaling. *Antioxid Redox Signal*. 2008; 10:1549–1564. [PubMed: 18479206]

8. Winterbourn CC, Hampton MB. Thiol chemistry and specificity in redox signaling. *Free Radic Biol Med.* 2008; 45:549–561. [PubMed: 18544350]
9. Sugamura K, Keaney JF Jr. Reactive oxygen species in cardiovascular disease. *Free Radic Biol Med.* 2011; 51(5):978–992. [PubMed: 21627987]
10. Benz CC, Yau C. Ageing, oxidative stress and cancer: paradigms in parallax. *Nat Rev Cancer.* 2008; 8(11):875–879. [PubMed: 18948997]
11. Sayre LM, Perry G, Smith MA. Oxidative stress and neurotoxicity. *Chem Res Toxicol.* 2008; 21(1):172–188. [PubMed: 18052107]
12. Zweier JL, Talukder HMA. The role of oxidants and free radicals in reperfusion injury. *Cardiovasc Res.* 2006; 70(2):181–190. [PubMed: 16580655]
13. Zweier, JL., Villamena, FA. Chemistry of free radicals in biological systems. In: Kukin, M., Fuster, V., editors. *Oxidative Stress and Cardiac Failure.* Futura Publishing; Armonk, NY, USA: 2003. p. 67-95.
14. Reddy MK, Wu L, Kou W, Ghorpade A, Labhasetwar V. Superoxide dismutase-loaded PLGA nanoparticles protect cultured human neurons under oxidative stress. *Appl Biochem Biotechnol.* 2008; 151(2–3):565–577. [PubMed: 18509606]
15. Christofidou-Solomidou M, Scherpereel A, Wiewrodt R, et al. PECAM-directed delivery of catalase to endothelium protects against pulmonary vascular oxidative stress. *Am J Physiol Lung Cell Mol Physiol.* 2003; 285(2):L283–L292. [PubMed: 12851209]
16. Lavu M, Gundewar S, Lefer DJ. Gene therapy for ischemic heart disease. *J Mol Cell Cardiol.* 2010; 50(5):742–750. [PubMed: 20600100]
17. Levonen A-L, Vaehakangas E, Koponen JK, Ylae-Herttuala S. Antioxidant gene therapy for cardiovascular disease: current status and future perspectives. *Circulation.* 2008; 117(16):2142–2150. [PubMed: 18427144]
18. Wu J, Hecker JG, Chiamvimonvat N. Antioxidant enzyme gene transfer for ischemic diseases. *Adv Drug Deliv Rev.* 2009; 61(4):351–363. [PubMed: 19233238]
19. Abunasra HJ, Smolenski RT, Morrison K, et al. Efficacy of adenoviral gene transfer with manganese superoxide dismutase and endothelial nitric oxide synthase in reducing ischemia and reperfusion injury. *Eur J Cardiothorac Surg.* 2001; 20(1):153–158. [PubMed: 11423289]
20. Li Q, Bolli R, Qiu Y, Tang XL, Guo Y, French BA. Gene therapy with extracellular superoxide dismutase protects conscious rabbits against myocardial infarction. *Circulation.* 2001; 103(14):1893–1898. [PubMed: 11294809]
21. de Haan JB, Cooper ME. Targeted antioxidant therapies in hyperglycemia-mediated endothelial dysfunction. *Front Biosci.* 2011; 3:709–729.
22. Nam SM, Lee MY, Koh JH, et al. Effects of NADPH oxidase inhibitor on diabetic nephropathy in OLETF rats: the role of reducing oxidative stress in its protective property. *Diabetes Res Clin Pract.* 2009; 83(2):176–182. [PubMed: 19111363]
23. Ogborne RM, Rushworth SA, O'Connell MA. Alpha-lipoic acid-induced heme oxygenase-1 expression is mediated by nuclear factor erythroid 2-related factor 2 and p38 mitogen-activated protein kinase in human monocytic cells. *Arterioscler Thromb Vasc Biol.* 2005; 25(10):2100–2105. [PubMed: 16123320]
24. Henriksen EJ, Diamond-Stanic MK, Marchionne EM. Oxidative stress and the etiology of insulin resistance and Type 2 diabetes. *Free Radic Biol Med.* 2011; 51(5):993–999. [PubMed: 21163347]
25. Vasu VT, de Cruz SJ, Houghton JS, et al. Evaluation of thiol-based antioxidant therapeutics in cystic fibrosis sputum: focus on myeloperoxidase. *Free Radic Res.* 2011; 45(2):165–176. [PubMed: 20954832]
26. Thomson MJ, Puntmann V, Kaski JC. Atherosclerosis and oxidant stress: the end of the road for antioxidant vitamin treatment? *Cardiovasc Drugs Ther.* 2007; 21(3):195–210. [PubMed: 17484034]
27. Brown BG, Cheung MC, Lee AC, Zhao XQ, Chait A. Antioxidant vitamins and lipid therapy: end of a long romance? *Arterioscler Thromb Vasc Biol.* 2002; 22(10):1535–1546. [PubMed: 12377728]

28. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. *N Engl J Med*. 2001; 345(22):1583–1592. [PubMed: 11757504]
29. Engler MM, Engler MB, Malloy MJ, et al. Antioxidant vitamins C and E improve endothelial function in children with hyperlipidemia: endothelial assessment of risk from lipids in youth (EARLY) trial. *Circulation*. 2003; 108(9):1059–1063. [PubMed: 12912807]
30. Sarkar, FH., Li, Y. Plant-derived antioxidants. In: Singh, KK., editor. *Oxidative Stress Disease and Cancer*. Imperial College Press; London, UK: 2006. p. 995-1011.
31. Packer, L., Cadenas, E. *Handbook of Synthetic Antioxidants*. Marcel Dekker, Inc.; NY, USA: 1997.
32. Lee BS, Yuan X, Xu Q, et al. Preparation and characterization of antioxidant nanospheres from multiple alpha-lipoic acid-containing compounds. *Bioorg Med Chem Lett*. 2009; 19(6):1678–1681. [PubMed: 19231184]
33. Kramer R. The pharmaceutical potential of manganese-based superoxide dismutase mimics. *Angew Chem Int Ed Engl*. 2000; 39(24):4469–4470. [PubMed: 11169638]
34. Biary N, Xie C, Kauffman J, Akar FG. Biophysical properties and functional consequences of reactive oxygen species (ROS)-induced ROS release in intact myocardium. *J Physiol*. 2011; 589(Pt 21):5167–5179. [PubMed: 21825030]
35. Findik E, Ceylan M, Elmastas M. Isoeugenol-based novel potent antioxidants: synthesis and reactivity. *Eur J Med Chem*. 2011; 46(9):4618–4624. [PubMed: 21843909]
36. Murias M, Handler N, Erker T, et al. Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship. *Bioorg Med Chem*. 2004; 12(21):5571–5578. [PubMed: 15465334]
37. Jomova K, Valko M. Importance of iron chelation in free radical-induced oxidative stress and human disease. *Curr Pharm Des*. 2011; 17(31):3460–3473. [PubMed: 21902663]
38. Heli H, Mirtorabi S, Karimian K. Advances in iron chelation: an update. *Expert Opin Ther Pat*. 2011; 21(6):819–856. [PubMed: 21449664]
39. Jomova K, Valko M. Advances in metal-induced oxidative stress and human disease. *Toxicology*. 2011; 283(2–3):65–87. [PubMed: 21414382]
40. Baek JH, Reiter CE, Manalo DJ, Buehler PW, Hider RC, Alayash AI. Induction of hypoxia inducible factor (HIF-1alpha) in rat kidneys by iron chelation with the hydroxypyridinone, CP94. *Biochim Biophys Acta*. 2011; 1809(4–6):262–268. [PubMed: 21558026]
41. Hoye AT, Davoren JE, Wipf P, Fink MP, Kagan VE. Targeting mitochondria. *Acc Chem Res*. 2008; 41(1):87–97. [PubMed: 18193822]
42. Soule BP, Hyodo F, Matsumoto K, et al. Therapeutic and clinical applications of nitroxide compounds. *Antioxid Redox Signal*. 2007; 9(10):1731–1743. [PubMed: 17665971]
43. Soule BP, Hyodo F, Matsumoto K, et al. The chemistry and biology of nitroxide compounds. *Free Radic Biol Med*. 2007; 42(11):1632–1650. [PubMed: 17462532]
44. Novelli GP, Angiolini P, Tani R, Consales G, Bordi L. Phenyl-t-butyl-nitrone is active against traumatic shock in rats. *Free Radical Res Commun*. 1986; 1(5):321–327. [PubMed: 3505231]
45. Novelli GP, Angiolini P, Livi P, Patheronostro E. Oxygen-derived free radicals in the pathogenesis of experimental shock. *Resuscitation*. 1989; 18(2–3):195–205. [PubMed: 2555873]
46. Maples KR, Green AR, Floyd RA. Nitron-related therapeutics: potential of NXY-059 for the treatment of acute ischaemic stroke. *CNS Drugs*. 2004; 18(15):1071–1084. [PubMed: 15581379]
47. Doggrell SA. Nitron spin on cerebral ischemia. *Curr Opin Investig Drugs*. 2006; 7(1):20–24.
48. Datta PK, Reddy S, Sharma M, Lianos EA. Differential nephron HO-1 expression following glomerular epithelial cell injury. *Nephron Exp Nephrol*. 2006; 103(4):e131–e138. [PubMed: 16601358]
49. Mandal MN, Moiseyev GP, Elliott MH, et al. Alpha-phenyl-*N-tert*-butylnitrone (PBN) prevents light-induced degeneration of the retina by inhibiting RPE65 protein isomerohydrolase activity. *J Biol Chem*. 2011; 286(37):32491–32501. [PubMed: 21785167]
50. Willis CL, Ray DE. Antioxidants attenuate MK-801-induced cortical neurotoxicity in the rat. *Neurotoxicology*. 2007; 28(1):161–167. [PubMed: 17141325]

51. Floyd RA. Nitrones as therapeutics in age-related diseases. *Aging Cell*. 2006; 5(1):51–57. [PubMed: 16441843]
52. Zhao Z, Cheng M, Maples KR, Ma JY, Buchan AM. NXY-059, a novel free radical trapping compound, reduces cortical infarction after permanent focal cerebral ischemia in the rat. *Brain Res*. 2001; 909(1–2):46–50. [PubMed: 11478919]
- 53■. Zuo L, Chen Y-R, Reyes LA, et al. The radical trap 5,5-dimethyl-1-pyrroline *N*-oxide exerts dose-dependent protection against myocardial ischemia-reperfusion injury through preservation of mitochondrial electron transport. *J Pharmacol Exp Ther*. 2009; 329(2):515–523. Underlying mechanisms of 5,5-dimethyl-1-pyrroline *N*-oxide protection against ROS-mediated ischemia and reperfusion injury. [PubMed: 19201989]
54. Floyd RA, Chandru HK, He T, Towner R. Anti-cancer activity of nitrones and observations on mechanism of action. *Anticancer Agents Med Chem*. 2011; 11(4):373–379. [PubMed: 21651461]
- 55■. Floyd RA, Kopke RD, Choi C-H, Foster SB, Doblas S, Towner RA. Nitrones as therapeutics. *Free Radic Biol Med*. 2008; 45(10):1361–1374. Discussion on the neuroprotective and anticancer property of nitron spin traps. [PubMed: 18793715]
56. Inoue Y, Asanuma T, Smith N, et al. Modulation of Fas-FasL related apoptosis by PBN in the early phases of choline deficient diet-mediated hepatocarcinogenesis in rats. *Free Radic Res*. 2007; 41(9):972–980. [PubMed: 17729114]
57. Nakae D, Kishida H, Enami T, et al. Effects of phenyl *N*-*tert*-butylnitron and its derivatives on the early phase of hepatocarcinogenesis in rats fed a choline-deficient, l-amino acid-defined diet. *Cancer Sci*. 2003; 94(1):26–31. [PubMed: 12708470]
58. He T, Doblas S, Saunders D, et al. Effects of PBN and OKN007 in rodent glioma models assessed by 1H MR spectroscopy. *Free Radic Biol Med*. 2011; 51(2):490–502. [PubMed: 21600283]
59. Garteiser P, Doblas S, Watanabe Y, et al. Multiparametric assessment of the antiglioma properties of OKN007 by magnetic resonance imaging. *J Magn Reson Imaging*. 2010; 31(4):796–806. [PubMed: 20373422]
60. Floyd Robert A, Towner Rheal A, Wu D, et al. Anti-cancer activity of nitrones in the Apc(Min/+) model of colorectal cancer. *Free Radic Res*. 2010; 44(1):108–117. [PubMed: 19886748]
- 61■. Locigno EJ, Zweier JL, Villamena FA. Nitric oxide release from the unimolecular decomposition of the superoxide radical anion adduct of cyclic nitrones in aqueous medium. *Org Biomol Chem*. 2005; 3(17):3220–3227. Demonstration of the nitric oxide release from the superoxide adduct of various nitrones. [PubMed: 16106305]
62. Yasui H, Ito N, Yamamori T, et al. Induction of neurite outgrowth by alpha-phenyl-*N*-*tert*-butylnitron through nitric oxide release and Ras-ERK pathway in PC12 cells. *Free Radic Res*. 2010; 44(6):645–654. [PubMed: 20370559]
63. Feuer, H. Nitrile Oxides, Nitrones, and Nitronates in Organic Synthesis. *Novel Strategies in Synthesis*. John Wiley & Sons, Inc.; NJ, USA: 2008.
- 64■. Rosen, GM., Britigan, BE., Halpern, HJ., Pou, S. *Free Radicals: Biology and Detection by Spin Trapping*. Oxford University Press; New York, NY, USA: 1999. Informative reference material for spin trapping
65. Gothelf KV, Jorgensen KA. Asymmetric 1,3-dipolar cycloaddition reactions. *Chem Rev*. 1998; 98(2):863–910. [PubMed: 11848917]
66. Villamena FA, Zweier JL. Detection of reactive oxygen and nitrogen species by EPR spin trapping. *Antioxid Redox Signal*. 2004; 6(3):619–629. [PubMed: 15130289]
67. Wong EHH, Junkers T, Barner-Kowollik C. Nitrones in synthetic polymer chemistry. *Polym Chem*. 2011; 2:1008–1017.
68. Afanasev I. Detection of superoxide in cells, tissues and whole organisms. *Front Biosci*. 2009; 1:153–160.
69. Chen CA, Druhan LJ, Varadharaj S, Chen YR, Zweier JL. Phosphorylation of endothelial nitric-oxide synthase regulates superoxide generation from the enzyme. *J Biol Chem*. 2008; 283(40):27038–27047. [PubMed: 18622039]
70. Druhan LJ, Forbes SP, Pope AJ, Chen CA, Zweier JL, Cardounel AJ. Regulation of eNOS-derived superoxide by endogenous methylarginines. *Biochemistry*. 2008; 47(27):7256–7263. [PubMed: 18553936]

71. Jia Z, Zhu H, Vitto MJ, Misra BR, Li Y, Misra HP. Alpha-lipoic acid potently inhibits peroxynitrite-mediated DNA strand breakage and hydroxyl radical formation: implications for the neuroprotective effects of alpha-lipoic acid. *Mol Cell Biochem.* 2009; 323(1–2):131–138. [PubMed: 19082545]
72. Pazos M, Andersen ML, Skibsted LH. Heme-mediated production of free radicals via preformed lipid hydroperoxide fragmentation. *J Agric Food Chem.* 2008; 56(23):11478–11484. [PubMed: 18998695]
73. Yoshii H, Yoshii Y, Asai T, Furukawa T, Takaichi S, Fujibayashi Y. Photo-excitation of carotenoids causes cytotoxicity via singlet oxygen production. *Biochem Biophys Res Commun.* 2012; 417(1): 640–645. [PubMed: 22185691]
74. Polyakov NE, Leshina TV, Meteleva ES, Dushkin AV, Konovalova TA, Kispert LD. Enhancement of the photocatalytic activity of TiO₂ nanoparticles by water-soluble complexes of carotenoids. *J Phys Chem B.* 2010; 114(45):14200–14204. [PubMed: 19968316]
75. Bosnjakovic A, Schlick S. Spin trapping by 5,5-dimethylpyrroline-*N*-oxide in Fenton media in the presence of nafion perfluorinated membranes: limitations and potential. *J Phys Chem B.* 2006; 110(22):10720–10728. [PubMed: 16771319]
76. Ionita P, Conte M, Gilbert BC, Chechik V. Gold nanoparticle-initiated free radical oxidations and halogen abstractions. *Org Biomol Chem.* 2007; 5(21):3504–3509. [PubMed: 17943210]
77. Fu H, Zhang L, Zhang S, Zhu Y, Zhao J. Electron spin resonance spin-trapping detection of radical intermediates in *N*-doped TiO₂-assisted photodegradation of 4-chlorophenol. *J Phys Chem B.* 2006; 110(7):3061–3065. [PubMed: 16494309]
78. Pou S, Pou WS, Bredt DS, Snyder SH, Rosen GM. Generation of superoxide by purified brain nitric oxide synthase. *J Biol Chem.* 1992; 267(34):24173–24176. [PubMed: 1280257]
79. Lambeth JD. NOX enzymes and the biology of reactive oxygen. *Nat Rev Immunol.* 2004; 4(3): 181–189. [PubMed: 15039755]
80. Koppenol WH. Oxygen activation by cytochrome p450: a thermodynamic analysis. *J Am Chem Soc.* 2007; 129(31):9686–9690. [PubMed: 17629268]
81. Robinson R, Sobrado P. Substrate binding modulates the activity of *Mycobacterium smegmatis* G, a flavin-dependent monooxygenase involved in the biosynthesis of hydroxamate-containing siderophores. *Biochemistry.* 2011; 50(39):8489–8496. [PubMed: 21870809]
82. Harrison R. Structure and function of xanthine oxidoreductase: where are we now? *Free Radic Biol Med.* 2002; 33(6):774–797. [PubMed: 12208366]
83. Chen Y-R, Chen C-L, Yeh A, Liu X, Zweier JL. Direct and indirect roles of cytochrome b in the mediation of superoxide generation and NO catabolism by mitochondrial succinate-cytochrome C reductase. *J Biol Chem.* 2006; 281(19):13159–13168. [PubMed: 16531408]
84. Bair JS, Palchaudhuri R, Hergenrother PJ. Chemistry and biology of deoxyxyboquinone, a potent inducer of cancer cell death. *J Am Chem Soc.* 2010; 132(15):5469–5478. [PubMed: 20345134]
85. Crisostomo AG, Moreno RB, Navaratnam S, Wilkinson JA, Bisby RH. Generation of superoxide and singlet oxygen from alpha-tocopherolquinone and analogues. *Free Radic Res.* 2007; 41(6): 730–737. [PubMed: 17516246]
86. Garg S, Rose AL, Waite TD. Production of reactive oxygen species on photolysis of dilute aqueous quinone solutions. *Photochem Photobiol.* 2007; 83:904–913. [PubMed: 17645662]
87. Zhao B, Bilski PJ, He YY, Feng L, Chignell CF. Photo-induced reactive oxygen species generation by different water-soluble fullerenes (C) and their cytotoxicity in human keratinocytes. *Photochem Photobiol.* 2008; 84(5):1215–1223. [PubMed: 18399919]
88. Sawyer DT, Valentine JS. How super is superoxide? *Acc Chem Res.* 1981; 14:393–400.
89. Kutala VK, Villamena FA, Ilangoan G, et al. Reactivity of superoxide anion radical with a perchlorotriphenylmethyl (trityl) radical. *J Phys Chem B.* 2008; 112(1):158–167. [PubMed: 18081340]
90. Rizzi C, Samouilov A, Kutala VK, Parinandi NL, Zweier JL, Kuppusamy P. Application of a trityl-based radical probe for measuring superoxide. *Free Radic Biol Med.* 2003; 35(12):1608–1618. [PubMed: 14680684]
91. Rosen GM, Rauckman EJ. Formation and reduction of a nitroxide radical by liver microsomes. *Biochem Pharmacol.* 1977; 26:675–678. [PubMed: 856200]

92. Rauckman EJ, Rosen GM, Kitchell BB. Superoxide radical as an intermediate in the oxidation of hydroxylamines by mixed function amine oxidase. *Mol Pharmacol*. 1979; 15:131–137. [PubMed: 34088]
93. Dikalov SI, Kirilyuk IA, Voinov M, Grigor'ev IA. EPR detection of cellular and mitochondrial superoxide using cyclic hydroxylamines. *Free Radic Res*. 2011; 45(4):417–430. [PubMed: 21128732]
94. Dikalov SI, Dikalova AE, Mason RP. Noninvasive diagnostic tool for inflammation-induced oxidative stress using electron spin resonance spectroscopy and an extracellular cyclic hydroxylamine. *Arch Biochem Biophys*. 2002; 402(2):218–226. [PubMed: 12051666]
95. Dikalov S, Grigor'ev IA, Voinov M, Bassenge E. Detection of superoxide radicals and peroxynitrite by 1-hydroxy-4-phosphonooxy-2,2,6,6-tetramethylpiperidine: quantification of extracellular superoxide radicals formation. *Biochem Biophys Res Commun*. 1998; 248(2):211–215. [PubMed: 9675114]
96. Hass HB, Riley EF. The nitro paraffins. *Chem Rev*. 1943; 32:373–430.
97. Rosen GM, Freeman BA. Detection of superoxide generated by endothelial cells. *Proc Natl Acad Sci USA*. 1984; 81:7269–7273. [PubMed: 6095281]
98. Sato E, Mokudai T, Niwano Y, Kamibayashi M, Kohno M. Existence of a new reactive intermediate oxygen species in hypoxanthine and xanthine oxidase reaction. *Chem Pharm Bull*. 2008; 56(8):1194–1197. [PubMed: 18670127]
99. Chen CL, Zhang L, Yeh A, et al. Site-specific S-glutathiolation of mitochondrial NADH ubiquinone reductase. *Biochemistry*. 2007; 46(19):5754–5765. [PubMed: 17444656]
100. Cheng Q, Antholine WE, Myers JM, Kalyanaraman B, Arner ES, Myers CR. The selenium-independent inherent pro-oxidant NADPH oxidase activity of mammalian thioredoxin reductase and its selenium-dependent direct peroxidase activities. *J Biol Chem*. 2010; 285(28):21708–21723. [PubMed: 20457604]
101. Sato E, Mokudai T, Niwano Y, Kohno M. Kinetic analysis of reactive oxygen species generated by the *in vitro* reconstituted NADPH oxidase and xanthine oxidase systems. *J Biochem*. 2011; 150(2):173–181. [PubMed: 21572100]
102. Shi H, Timmins G, Monske M, et al. Evaluation of spin trapping agents and trapping conditions for detection of cell-generated reactive oxygen species. *Arch Biochem Biophys*. 2005; 437(1):59–68. [PubMed: 15820217]
103. Karakawa T, Sato K, Muramoto Y, et al. Applicability of new spin trap agent, 2-diphenylphosphinoyl-2-methyl-3,4-dihydro-2H-pyrrole *N*-oxide, in biological system. *Biochem Biophys Res Commun*. 2008; 370(1):93–97. [PubMed: 18355451]
104. Zweier JL, Kuppusamy P, Williams R, et al. Measurement and characterization of postischemic free radical generation in the isolated perfused heart. *J Biol Chem*. 1989; 264(32):18890–18895. [PubMed: 2553726]
105. Kadiiska MB, Ghio AJ, Mason RP. ESR investigation of the oxidative damage in lungs caused by asbestos and air pollution particles. *Spectrochim Acta A Mol Biomol Spectrosc*. 2004; 60(6):1371–1377. [PubMed: 15134737]
106. Bolli R, Jeroudi MO, Patel BS, et al. Direct evidence that oxygen-derived free radicals contribute to postischemic myocardial dysfunction in the intact dog. *Proc Natl Acad Sci USA*. 1989; 86(12):4695–4699. [PubMed: 2543984]
107. Zweier JL, Flaherty JT, Weisfeldt ML. Direct measurement of free radical generation following reperfusion of ischemic myocardium. *Proc Natl Acad Sci USA*. 1987; 84(5):1404–1407. [PubMed: 3029779]
108. Ebersson, L. Spin-trapping: problems and artefacts. In: Rhodes, CJ., editor. *Toxicology of the Human Environment: The Critical Role of Free Radicals*. Taylor Francis; New York, NY, USA: 2000. p. 25–48.
109. Rangelova K, Mason RP. The fidelity of spin trapping with DMPO in biological systems. *Magn Reson Chem*. 2011; 49(4):152–158. [PubMed: 21246623]
110. Potapenko DI, Clanton TL, Bagryanskaya EG, Gritsan NP, Reznikov VA, Khramtsov VV. Nonradical mechanism of (bi)sulfite reaction with DEPMPO: cautionary note for SO₃^{•-} radical spin trapping. *Free Radic Biol Med*. 2003; 34(2):196–206. [PubMed: 12521601]

111. Finkelstein E, Rosen GM, Rauckman EJ, Paxton J. Spin trapping of superoxide. *Mol Pharmacol*. 1979; 16(2):676–685. [PubMed: 229403]
112. Finkelstein E, Rosen GM, Rauckman EJ. Superoxide radical anion 5,5-dimethyl-1-pyrroline-1-oxyl. *J Am Chem Soc*. 1980; 102:4994–4999.
113. Villamena FA, Hadad CM, Zweier JL. Kinetic study and theoretical analysis of hydroxyl radical trapping and spin adduct decay of alkoxy carbonyl- and dialkoxylphosphoryl-nitrones in aqueous media. *J Phys Chem A*. 2003; 107:4407–4414.
114. Villamena FA, Zweier JL. Superoxide radical trapping and spin adduct decay of 5-*tert*-butoxycarbonyl-5-methyl-1-pyrroline *N*-oxide (BocMPO): kinetics and theoretical analysis. *J Chem Soc Perkin Trans*. 2002; 2(7):1340–1344.
115. Villamena FA, Hadad CM, Zweier JL. Theoretical study of the spin trapping of hydroxyl radical by cyclic nitrones: a density functional theory approach. *J Am Chem Soc*. 2004; 126:1816–1829. [PubMed: 14871114]
116. Villamena FA, Hadad CM, Zweier JL. Comparative DFT study of the spin trapping of methyl, mercapto, hydroperoxy, superoxide, and nitric oxide radicals by various substituted cyclic nitrones. *J Phys Chem A*. 2005; 109(8):1662–1674. [PubMed: 16833491]
117. Boyd SL, Boyd RJ. A theoretical study of spin trapping by nitron: trapping of hydrogen, methyl, hydroxyl, and peroxy radicals. *J Phys Chem*. 1994; 98(45):11705–11713.
118. Buettner GR. The pecking order of free radicals and antioxidants: lipid peroxidation, α -tocopherol and ascorbate. *Arch Biochem Biophys*. 1993; 300:535–543. [PubMed: 8434935]
119. Das TN, Huie RE, Neta P, Padmaja S. Reduction potential of the sulfhydryl radical: pulse radiolysis and laser flash photolysis studies of the formation and reactions of $\bullet\text{SH}$ and $\text{HSSH}\bullet^-$ in aqueous solutions. *J Phys Chem A*. 1999; 103:5221–5226.
120. Bartberger MD, Liu W, Ford E, et al. The reduction potential of nitric oxide (NO) and its importance to NO biochemistry. *Proc Natl Acad Sci USA*. 2002; 99(17):10958–10963. [PubMed: 12177417]
121. Villamena F, Hadad CM, Zweier J. Kinetic study and theoretical analysis of hydroxyl radical trapping and spin adduct decay of alkoxy carbonyl- and dialkoxylphosphoryl-nitrones in aqueous media. *J Phys Chem A*. 2003; 107:4407–4414.
122. Pou S, Ramos CL, Gladwell T, et al. A kinetic approach to the selection of a sensitive spin trapping system for the detection of hydroxyl radical. *Anal Biochem*. 1994; 217(1):76–83. [PubMed: 8203741]
123. Davies MJ, Forni LG, Shuter SL. Electron spin resonance and pulse radiolysis studies on the spin trapping of sulphur-centered radicals. *Chem Biol Interact*. 1987; 61:177–188. [PubMed: 3030572]
124. Finkelstein E, Rosen GM, Rauckman EJ. Spin trapping. Kinetics of the reaction of superoxide and hydroxyl radicals with nitrones. *J Am Chem Soc*. 1980; 102(15):4994–4999.
125. Villamena F, Zweier J. Superoxide radical trapping and spin adduct decay of 5-*tert*-butoxycarbonyl-5-methyl-1-pyrroline *N*-oxide (BocMPO): kinetics and theoretical analysis. *J Chem Soc Perkin Trans*. 2002; 2:1340–1344.
126. Tsai P, Ichikawa K, Mailer C, et al. Esters of 5-carboxyl-5-methyl-1-pyrroline *N*-oxide: a family of spin traps for superoxide. *J Org Chem*. 2003; 68(20):7811–7817. [PubMed: 14510560]
127. Villamena FA, Xia S, Merle JK, et al. Reactivity of superoxide radical anion with cyclic nitrones: role of intramolecular H-bond and electrostatic effects. *J Am Chem Soc*. 2007; 129(26):8177–8191. [PubMed: 17564447]
128. Durand G, Choteau F, Pucci B, Villamena FA. Reactivity of superoxide radical anion and hydroperoxyl with α -phenyl-*N*-*tert*-butylnitron (PBN) derivatives. *J Phys Chem A*. 2008; 112(48):12498–12509. [PubMed: 18998656]
129. Issacs, NS. *Physical Organic Chemistry*. Longman Scientific and Technical; Essex, UK: 1987.
130. Ren Y, Yamataka H. The α -effect in gas-phase $\text{S}_\text{N}2$ reactions: existence and the origin of the effect. *J Org Chem*. 2007; 72:5660–5667. [PubMed: 17590049]
131. Han Y, Tuccio B, Lauricella R, Villamena FA. Improved spin trapping properties by beta-cyclodextrin-cyclic nitron conjugate. *J Org Chem*. 2008; 73(18):7108–7117. [PubMed: 18707169]

132. Han Y, Liu Y, Rockenbauer A, Zweier JL, Durand G, Villamena FA. Lipophilic beta-cyclodextrin cyclic-nitrone conjugate: synthesis and spin trapping studies. *J Org Chem.* 2009; 74(15):5369–5380. [PubMed: 19530689]
133. Kim SU, Liu Y, Nash KM, Zweier JL, Rockenbauer A, Villamena FA. Fast reactivity of a cyclic nitrone-calix[4]pyrrole conjugate with superoxide radical anion: theoretical and experimental studies. *J Am Chem Soc.* 2010 Epub ahead of print. Demonstration of nitrone design with enhanced reactivity to superoxide and long half-life for its superoxide adduct.
134. Field SM, Villamena FA. Theoretical and experimental studies of tyrosyl hydroperoxide formation in the presence of H-bond donors. *Chem Res Toxicol.* 2008; 21(10):1923–1932. [PubMed: 18816073]
135. Winterbourn CC, Parsons-Mair HN, Gebicki S, Gebicki JM, Davies MJ. Requirements for superoxide-dependent tyrosine hydroperoxide formation in peptides. *Biochem J.* 2004; 381(Part 1):241–248. [PubMed: 15025556]
136. Allouch A, Lauricella RP, Tuccio BN. Effect of pH on superoxide/hydroperoxyl radical trapping by nitrones: an EPR/kinetic study. *Mol Phys.* 2007; 105(15–16):2017–2024.
137. Behar D, Czapski G, Rabani J, Dorfman LM, Schwarz HA. Acid dissociation constant and decay kinetics of the perhydroxyl radical. *J Phys Chem.* 1970; 74(17):3209–3213.
138. Czapski G, Bielski BHJ. The formation and decay of H_2O_3 and HO_2 in electronirradiated aqueous solutions. *J Phys Chem.* 1963; 67(10):2180–2184.
139. Villamena FA, Merle JK, Hadad CM, Zweier JL. Rate constants of hydroperoxyl radical addition to cyclic nitrones: a DFT study. *J Phys Chem A.* 2007; 111(39):9995–10001. [PubMed: 17845014]
140. Burgett RA, Bao X, Villamena FA. Superoxide radical anion adduct of 5,5-dimethyl-1-pyrroline *N*-oxide (DMPO). 3. Effect of mildly acidic pH on the thermodynamics and kinetics of adduct formation. *J Phys Chem A.* 2008; 112(11):2447–2455. [PubMed: 18303874]
141. Hertz L. Bioenergetics of cerebral ischemia: a cellular perspective. *Neuropharmacology.* 2008; 55(3):289–309. [PubMed: 18639906]
142. Isaev NK, Stelmashook EV, Plotnikov EY, et al. Role of acidosis, NMDA receptors, and acid-sensitive ion channel 1a (ASIC1a) in neuronal death induced by ischemia. *Biochemistry.* 2008; 73(11):1171–1175. [PubMed: 19120019]
143. Niwano S, Tojo T. Systemic acidosis in acute myocardial ischemia – cause or result of life-threatening ventricular arrhythmia? *Circ J.* 2010; 74(9):1794–1795. [PubMed: 20702957]
144. Inserte J, Ruiz-Meana M, Rodriguez-Sinovas A, Barba I, Garcia-Dorado D. Contribution of delayed intracellular pH recovery to ischemic postconditioning protection. *Antioxid Redox Signal.* 2011; 14(5):923–939. [PubMed: 20578958]
145. Villamena FA, Locigno EJ, Rockenbauer A, Hadad CM, Zweier JL. Theoretical and experimental studies of the spin trapping of inorganic radicals by 5,5-dimethyl-1-pyrroline *N*-oxide (DMPO). 1. Carbon dioxide radical anion. *J Phys Chem A.* 2006; 110(49):13253–13258. [PubMed: 17149843]
146. Villamena FA, Locigno EJ, Rockenbauer A, Hadad CM, Zweier JL. Theoretical and experimental studies of the spin trapping of inorganic radicals by 5,5-dimethyl-1-pyrroline *N*-oxide (DMPO). 2. Carbonate radical anion. *J Phys Chem A.* 2007; 111(2):384–391. [PubMed: 17214476]
147. Dikalova AE, Kadiiska MB, Mason RP. An *in vivo* ESR spin-trapping study: free radical generation in rats from formate intoxication-role of the Fenton reaction. *Proc Natl Acad Sci USA.* 2001; 98(24):13549–13553. [PubMed: 11717423]
148. LaCagnin LB, Connor HD, Mason RP, Thurman RG. The carbon dioxide anion radical adduct in the perfused rat liver: relationship to halocarbon-induced toxicity. *Mol Pharmacol.* 1988; 33:351–357. [PubMed: 2832723]
149. Rau JM, Reinke LA, McCay PB. Direct observation of spin-trapped carbon dioxide radicals in hepatocytes exposed to carbon tetrachloride. *Free Radic Res Commun.* 1990; 9(3–6):197–204. [PubMed: 2167257]
150. Imaram W, Saylor BT, Centonze CP, Richards NG, Angerhofer A. EPR spin trapping of an oxalate-derived free radical in the oxalate decarboxylase reaction. *Free Radic Biol Med.* 2011; 50(8):1009–1015. [PubMed: 21277974]

151. Krapf R, Beeler I, Hertner D, Hultner HN. Chronic respiratory alkalosis. The effect of sustained hyperventilation on renal regulation of acid-base equilibrium. *N Engl J Med.* 1991; 324:1394–1401. [PubMed: 1902283]
152. Wesson DE. Dietary HCO_3^- reduces distal tubule acidification by increasing cellular HCO_3^- secretion. *Am J Physiol.* 1996; 271:F132–F142. [PubMed: 8760254]
153. Karunakaran C, Zhang H, Joseph J, Antholine WE, Kalyanaraman B. Thiol oxidase activity of copper, zinc superoxide dismutase stimulates bicarbonate-dependent peroxidase activity via formation of a carbonate radical. *Chem Res Toxicol.* 2005; 18:494–500. [PubMed: 15777089]
154. Zhang H, Joseph J, Felix C, Kalyanaraman B. Bicarbonate enhances the hydroxylation, nitration, and peroxidation reactions catalyzed by copper, zinc superoxide dismutase. Intermediacy of carbonate anion radical. *J Biol Chem.* 2000; 275:14038–14045. [PubMed: 10799477]
155. Zhang H, Joseph J, Gurney M, Becker D, Kalyanaraman B. Bicarbonate enhances peroxidase activity of Cu, Zn-superoxide dismutase. Role of carbonate anion radical and scavenging of carbonate anion radical by metalloporphyrin antioxidant enzyme mimetics. *J Biol Chem.* 2002; 277(2):1013–1020. [PubMed: 11682485]
156. Squadrito GL, Pryor WA. Mapping the reaction of peroxynitrite with CO_2 : energetics, reactive species, and biological implications. *Chem Res Toxicol.* 2002; 15(7):885–895. [PubMed: 12118998]
157. Rangelova K, Chatterjee S, Ehrenshaft M, et al. Protein radical formation resulting from eosinophil peroxidase-catalyzed oxidation of sulfite. *J Biol Chem.* 2010; 285(31):24195–24205. [PubMed: 20501663]
158. Sun X, Shi X, Dalal NS. Xanthine oxidase/hydrogen peroxide generates sulfur trioxide anion radical (SO_3^{2-}) from sulfite (SO_3^{2-}). *FEBS Lett.* 1992; 303(2–3):213–216. [PubMed: 1318848]
159. Rangelova K, Bonini MG, Mason RP. (Bi) sulfite oxidation by copper, zinc-superoxide dismutase: sulfite-derived, radical-initiated protein radical formation. *Environ Health Perspect.* 2010; 118(7):970–975. [PubMed: 20348042]
160. Alipazaga MV, Moreno RG, Linares E, Medeiros MH, Coichev N. DNA damage by sulfite autoxidation catalyzed by cobalt complexes. *Dalton Trans.* 2008; 41:5636–5644.
161. Rangelova K, Mason RP. New insights into the detection of sulfur trioxide anion radical by spin trapping: radical trapping versus nucleophilic addition. *Free Radic Biol Med.* 2009; 47:128–134. [PubMed: 19362142]
162. Elias RJ, Andersen ML, Skibsted LH, Waterhouse AL. Identification of free radical intermediates in oxidized wine using electron paramagnetic resonance spin trapping. *J Agric Food Chem.* 2009; 57:4359–4365.
163. Potapenko DI, Bagryanskaya EG, Tsentalovich YP, Reznikov VA, Clanton TL, Khramtsov VV. Reversible reactions of thiols and thiol radicals with nitron spin traps. *J Phys Chem B.* 2004; 108:9315–9324.
164. Astolfi P, Greci L, Panagiotaki M. Spin trapping of nitrogen dioxide and of radicals generated from nitrous acid. *Free Radic Res.* 2005; 39(2):137–144. [PubMed: 15763961]
165. Gatti RM, Alvarez B, Vasquez-Vivar J, Radi R, Augusto O. Formation of spin trap adducts during the decomposition of peroxynitrite. *Arch Biochem Biophys.* 1998; 349(1):36–46. [PubMed: 9439580]
166. Kalyanaraman B, Janzen EG, Mason RP. Spin trapping of the azidyl radical in azide/catalase/hydrogen peroxide and various azide/peroxidase/hydrogen peroxide peroxidizing systems. *J Biol Chem.* 1985; 260:4003–4006. [PubMed: 2984193]
167. Partridge RS, Monroe SM, Parks JK, et al. Spin trapping of azidyl and hydroxyl radicals in azide-inhibited rat brain submitochondrial particles. *Arch Biochem Biophys.* 1994; 310(1):210–217. [PubMed: 8161207]
168. Leinisch F, Rangelova K, DeRose EF, Jiang JJ, Mason RP. Evaluation of the Forrester–Hepburn mechanism as an artifact source in ESR spin-trapping. *Chem Res Toxicol.* 2012; 24(12):2217–2226.
169. Akaike T, Yoshida M, Miyamoto Y, et al. Antagonistic action of imidazolineoxyl *N*-oxides against endothelium-derived relaxing factor/NO through a radical reaction. *Biochemistry.* 1993; 32(3):827–832. [PubMed: 8422387]

170. Vanin AF, Mordvintcev PI, Hauschildt S, Mulsch A. The relationship between l-arginine-dependent nitric oxide synthesis, nitrite release and dinitrosyl-iron complex formation by activated macrophages. *Biochim Biophys Acta*. 1993; 1177(1):37–42. [PubMed: 8387340]
171. Pou S, Tsai P, Porasuphatana S, et al. Spin trapping of nitric oxide by ferro-chelates: kinetic and *in vivo* pharmacokinetic studies. *Biochim Biophys Acta*. 1999; 1427(2):216–226. [PubMed: 10216238]
172. Stubbe J, van der Donk WA. Protein radicals in enzyme catalysis. *Chem Rev*. 1998; 98(2):705–762. [PubMed: 11848913]
173. Augusto O, Lopes de Menezes S, Linares E, Romero N, Radi R, Denicola A. EPR detection of glutathionyl and hemoglobin-cysteinyl radicals during the interaction of peroxynitrite with human erythrocytes. *Biochemistry*. 2002; 41(48):14323–14328. [PubMed: 12450398]
174. Gomez-Mejiba SE, Zhai Z, Akram H, et al. Immuno-spin trapping of protein and DNA radicals: “tagging” free radicals to locate and understand the redox process. *Free Radic Biol Med*. 2009; 46(7):853–865. [PubMed: 19159679]
175. Mason RP. Using anti-5,5-dimethyl-1-pyrroline *N*-oxide (anti-DMPO) to detect protein radicals in time and space with immuno-spin trapping. *Free Radic Biol Med*. 2004; 36(10):1214–1223. [PubMed: 15110386]
176. Chatterjee S, Ehrenshaft M, Bhattacharjee S, et al. Immuno-spin trapping of a post-translational carboxypeptidase B1 radical formed by a dual role of xanthine oxidase and endothelial nitric oxide synthase in acute septic mice. *Free Radic Biol Med*. 2009; 46(4):454–461. [PubMed: 19049863]
177. Bhattacharjee S, Deterding LJ, Jiang J, et al. Electron transfer between a tyrosyl radical and a cysteine residue in hemoproteins: spin trapping analysis. *J Am Chem Soc*. 2007; 129(44):13493–13501. [PubMed: 17939657]
178. Chen Y-R, Chen C-L, Liu X, Li H, Zweier JL, Mason RP. Involvement of protein radical, protein aggregation, and effects on NO metabolism in the hypochlorite-mediated oxidation of mitochondrial cytochrome c. *Free Radic Biol Med*. 2004; 37(10):1591–1603. [PubMed: 15477010]
179. Dikalov SI, Mason RP. Spin trapping of polyunsaturated fatty acid-derived peroxy radicals: reassignment to alkoxyl radical adducts. *Free Radic Biol Med*. 2001; 30:187–197. [PubMed: 11163536]
180. Stolze K, Udilova N, Rosenau T, Hofinger A, Nohl H. Spin trapping of superoxide, alkyl- and lipid-derived radicals with derivatives of the spin trap EPPN. *Biochem Pharmacol*. 2003; 66(9):1717–1726. [PubMed: 14563482]
181. Yu Q, Purwaha P, Ni K, Sun C, Mallik S, Qian SY. Characterization of novel radicals from COX-catalyzed arachidonic acid peroxidation. *Free Radic Biol Med*. 2009; 47(5):568–576. [PubMed: 19482075]
182. Xiao Y, Gu Y, Purwaha P, et al. Characterization of free radicals formed from COX-catalyzed DGLA peroxidation. *Free Radic Biol Med*. 2011; 50(9):1163–1170. [PubMed: 21310230]
183. Reis A, Domingues P, Ferrer-Correia AJ, Domingues MR. Identification of free radicals of glycerophosphatidylcholines containing omega-6 fatty acids using spin trapping coupled with tandem mass spectrometry. *Free Radic Res*. 2007; 41(4):432–443. [PubMed: 17454125]
184. Qian SY, Guo Q, Mason RP. Identification of spin trapped carbon-centered radicals in soybean lipoxygenase-dependent peroxidations of ω -3 polyunsaturated fatty acids by LC/ESR, LC/MS, and tandem MS. *Free Radic Biol Med*. 2003; 35:33–44. [PubMed: 12826254]
185. Samuni A, Krishna CM, Mitchell JB, Collins CR, Russo A. Superoxide reaction with nitroxides. *Free Radic Res Commun*. 1990; 9(3–6):241–249. [PubMed: 2167262]
186. Finkelstein E, Rosen GM, Rauckman EJ. Superoxide-dependent reduction of nitroxides by thiols. *Biochim Biophys Acta*. 1984; 802:90–98.
187. Villamena FA. Superoxide radical anion adduct of 5,5-dimethyl-1-pyrroline *N*-oxide. 6: redox properties. *J Phys Chem A*. 2010; 114(2):1153–1160. [PubMed: 19968309]
188. Miller MJ. Syntheses and therapeutic potential of hydroxamic acid based siderophores and analogs. *Chem Rev*. 1989; 89:1563–1579.

189. Karagiannis TC, El-Osta A. Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds? *Leukemia*. 2007; 21:61–65. [PubMed: 17109024]
190. Marmion CJ, Griffith D, Nolan KB. Hydroxamic acids – an intriguing family of enzyme inhibitors and biomedical ligands. *Eur J Inorg Chem*. 2004; 15:3003–3016.
191. Lauricella R, Allouch A, Roubaud V, Bouteiller JC, Tuccio B. A new kinetic approach to the evaluation of rate constants for the spin trapping of superoxide/hydroperoxyl radical by nitrones in aqueous media. *Org Biomol Chem*. 2004; 2(9):1304–1309. [PubMed: 15105920]
192. Lauricella RP, Bouteiller JC, Tuccio BN. Evidence of overestimation of rate constants for the superoxide trapping by nitrones in aqueous media. *Phys Chem Chem Phys*. 2005; 7(2):399–404. [PubMed: 19785165]
193. Samuni A, Krishna CM, Riesz P, Finkelstein E, Russo A. Superoxide reaction with nitroxide spin-adducts. *Free Radic Biol Med*. 1989; 6(2):141–148. [PubMed: 2540065]
194. Buettner GR, Oberley LM. Considerations in the spin trapping of superoxide and hydroxyl radical in aqueous systems using 5,5-dimethyl-1-pyrroline-*N*-oxide. *Biochem Biophys Res Commun*. 1978; 83(1):69–74. [PubMed: 212052]
195. Zhang R, Goldstein S, Samuni A. Kinetics of superoxide-induced exchange among nitroxide antioxidants and their oxidized and reduced forms. *Free Radic Biol Med*. 1999; 26(9–10):1245–1252. [PubMed: 10381196]
196. Samuni A, Goldstein S, Russo A, Mitchell JB, Krishna MC, Neta P. Kinetics and mechanism of hydroxyl radical and OH-adduct radical reactions with nitroxides and with their hydroxylamines. *J Am Chem Soc*. 2002; 124(29):8719–8724. [PubMed: 12121116]
197. Zhang R, Pinson A, Samuni A. Both hydroxylamine and nitroxide protect cardiomyocytes from oxidative stress. *Free Radic Biol Med*. 1998; 24(1):66–75. [PubMed: 9436615]
198. Frejaville C, Karoui H, Tuccio B, et al. 5-(diethoxyphosphoryl)-5-methyl-1-pyrroline *N*-oxide: a new efficient phosphorylated nitron for the *in vitro* and *in vivo* spin trapping of oxygen-centered radicals. *J Med Chem*. 1995; 38(2):258–265. [PubMed: 7830268]
199. Stolze K, Udilova N, Rosenau T, Hofinger A, Nohl H. Synthesis and characterization of EMPO-derived 5,5-disubstituted 1-pyrroline *N*-oxides as spin traps forming exceptionally stable superoxide spin adducts. *Biol Chem*. 2003; 384(3):493–500. [PubMed: 12715901]
200. Frejaville C, Karoui H, Tuccio B, et al. 5-diethoxyphosphoryl-5-methyl-1-pyrroline *N*-oxide (DEPMPO): a new phosphorylated nitron for the efficient *in vitro* and *in vivo* spin trapping of oxygen-centered radicals. *J Chem Soc Chem Commun*. 1994; 15:1793–1794.
201. Villamena FA, Rockenbauer A, Gallucci J, Velayutham M, Hadad CM, Zweier JL. Spin trapping by 5-carbamoyl-5-methyl-1-pyrroline *N*-oxide (AMPO): theoretical and experimental studies. *J Org Chem*. 2004; 69(23):7994–8004. [PubMed: 15527282]
202. Villamena FA. Superoxide radical anion adduct of 5,5-dimethyl-1-pyrroline *N*-oxide. 5. Thermodynamics and kinetics of unimolecular decomposition. *J Phys Chem A*. 2009; 113:6398–6403. [PubMed: 19425559]
203. Wang, PG., Cai, TB., Taniguchi, N. Nitric Oxide Donors. Wiley-VCH Verlag Gmbh and Co.; Weinheim, Germany: 2005.
204. Allouch A, Roubaud V, Lauricella R, Bouteiller J-C, Tuccio B. Preparation and use as spin trapping agents of new ester-nitrones. *Org Biomol Chem*. 2003; 1(3):593–598. [PubMed: 12926265]
205. Stolze K, Udilova N, Nohl H. Spin trapping of lipid radicals with DEPMPO-derived spin traps: detection of superoxide, alkyl and alkoxyl radicals in aqueous and lipid phase. *Free Radic Biol Med*. 2000; 29:1005–1014. [PubMed: 11084289]
206. Stolze K, Udilova N, Nohl H. Spin adducts of superoxide, alkoxyl, and lipid-derived radicals with EMPO and its derivatives. *Biol Chem*. 2002; 383(5):813–820. [PubMed: 12108546]
207. Streeter J, Thiel W, Brieger K, Miller FJ Jr. Opportunity Nox: the future of NADPH oxidases as therapeutic targets in cardiovascular disease. *Cardiovasc Ther*. 2012 Epub ahead of print.
208. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. *Physiol Rev*. 2007; 87(1):245–313. [PubMed: 17237347]

209. Zhang Y, Janssens SP, Wingler K, Schmidt HH, Moens AL. Modulating endothelial nitric oxide synthase: a new cardiovascular therapeutic strategy. *Am J Physiol Heart Circ Physiol*. 2011; 301(3):H634–H646. [PubMed: 21622818]
210. Benderitter M, Vincent-Genod L, Pouget JP, Voisin P. The cell membrane as a biosensor of oxidative stress induced by radiation exposure: a multiparameter investigation. *Radiat Res*. 2003; 159(4):471–483. [PubMed: 12643792]
211. Jacob RF, Mason RP. Lipid peroxidation induces cholesterol domain formation in model membranes. *J Biol Chem*. 2005; 280:39380–39387. [PubMed: 16195227]
212. Hardy M, Ouari O, Charles L, et al. Synthesis and spin-trapping behavior of 5-ChEPMPPO, a cholesteryl ester analogue of the spin trap DEPMPO. *J Org Chem*. 2005; 70(25):10426–10433. [PubMed: 16323853]
213. Gosset G, Clement J-L, Culcasi M, Rockenbauer A, Pietri S. CyDEPMPOs: a class of stable cyclic DEPMPO derivatives with improved properties as mechanistic markers of stereoselective hydroxyl radical adduct formation in biological systems. *Bioorg Med Chem*. 2011; 19:2218–2230. [PubMed: 21420303]
214. Sar CP, Osz E, Jeko J, Hideg K. Synthesis of spiro[pyrrolidine-2,2'-adamantane] nitrones and nitroxides. *Synthesis*. 2005; (2):255–259.
215. Stolze K, Udilova N, Rosenau T, Hofinger A, Nohl H. Spin adduct formation from lipophilic EMPO-derived spin traps with various oxygen- and carbon-centered radicals. *Biochem Pharmacol*. 2005; 69(2):297–305. [PubMed: 15627482]
216. Symons AM, King LJ. Inflammation, reactive oxygen species and cytochrome P450. *Inflammopharmacology*. 2003; 11(1):75–86. [PubMed: 15035735]
217. Sato M, Yokoyama U, Fujita T, Okumura S, Ishikawa Y. The roles of cytochrome p450 in ischemic heart disease. *Curr Drug Metab*. 2011; 12(6):526–532. [PubMed: 21476972]
218. Kundu TK, Hille R, Velayutham M, Zweier JL. Characterization of superoxide production from aldehyde oxidase: an important source of oxidants in biological tissues. *Arch Biochem Biophys*. 2007; 460(1):113–121. [PubMed: 17353002]
219. Kundu TK, Velayutham M, Zweier JL. Aldehyde oxidase functions as a superoxide generating NADH oxidase: an important redox regulated pathway of cellular oxygen radical formation. *Biochemistry*. 2012; 51(13):2930–2939. [PubMed: 22404107]
220. Lee BE, Toledo AH, Anaya-Prado R, Roach RR, Toledo-Pereyra LH. Allopurinol, xanthine oxidase, and cardiac ischemia. *J Investig Med*. 2009; 57(8):902–909.
221. Garattini E, Terao M. The role of aldehyde oxidase in drug metabolism. *Expert Opin Drug Metab Toxicol*. 2012; 8(4):487–503. [PubMed: 22335465]
222. Le Bourdonnec B, Leister LK. Medicinal chemistry strategies to reduce CYP2D6 inhibitory activity of lead candidates. *Curr Med Chem*. 2009; 16(24):3093–3121. [PubMed: 19689286]
223. Torres RA, Korzekwa KR, McMasters DR, Fandozzi CM, Jones JP. Use of density functional calculations to predict the regioselectivity of drugs and molecules metabolized by aldehyde oxidase. *J Med Chem*. 2007; 50(19):4642–4647. [PubMed: 17718551]
224. Rosen GM, Tsai P, Pou S. Mechanism of free-radical generation by nitric oxide synthase. *Chem Rev*. 2002; 102(4):1191–1200. [PubMed: 11942793]
225. Wei CC, Crane BR, Stuehr DJ. Tetrahydrobiopterin radical enzymology. *Chem Rev*. 2003; 103(6):2365–2383. [PubMed: 12797834]
226. Seyednejad H, Ghassemi AH, van Nostrum CF, Vermonden T, Hennink WE. Functional aliphatic polyesters for biomedical and pharmaceutical applications. *J Control Release*. 2011; 152(1):168–176. [PubMed: 21223989]
227. Burks SR, Ni J, Muralidharan S, Coop A, Kao JP, Rosen GM. Optimization of labile esters for esterase-assisted accumulation of nitroxides into cells: a model for *in vivo* EPR imaging. *Bioconjug Chem*. 2008; 19(10):2068–2071. [PubMed: 18783260]
228. Kao JP, Rosen GM. Esterase-assisted accumulation of 3-carboxy-2,2,5,5-tetramethyl-1-pyrrolidinyloxy into lymphocytes. *Org Biomol Chem*. 2004; 2(1):99–102. [PubMed: 14737666]
229. Allouch A, Roubaud V, Lauricella R, Bouteiller J-C, Tuccio B. Spin trapping of superoxide by diester-nitrones. *Org Biomol Chem*. 2005; 3(13):2458–2462. [PubMed: 15976863]

230. Zhao H, Joseph J, Zhang H, Karoui H, Kalyanaraman B. Synthesis and biochemical applications of a solid cyclic nitron spin trap: a relatively superior trap for detecting superoxide anions and glutathyl radicals. *Free Radic Biol Med*. 2001; 31(5):599–606. [PubMed: 11522444]
231. Ong SB, Gustafsson AB. New roles for mitochondria in cell death in the reperfused myocardium. *Cardiovasc Res*. 2011; 94(2):190–196. [PubMed: 22108916]
232. Schapira AH, Gegg M. Mitochondrial contribution to Parkinson's disease pathogenesis. *Parkinsons Dis*. 2011; 2011:159160. [PubMed: 21687805]
233. Ramalingam M, Kim SJ. Reactive oxygen/nitrogen species and their functional correlations in neurodegenerative diseases. *J Neural Transm*. 2012 Epub ahead of print.
234. Teixeira J, Soares P, Benfeito S, et al. Rational discovery and development of a mitochondria-targeted antioxidant based on cinnamic acid scaffold. *Free Radic Res*. 2012; 46(5):600–611. [PubMed: 22292941]
235. Dong LF, Jameson VJ, Tilly D, et al. Mitochondrial targeting of alpha-tocopheryl succinate enhances its pro-apoptotic efficacy: a new paradigm for effective cancer therapy. *Free Radic Biol Med*. 2011; 50(11):1546–1555. [PubMed: 21402148]
236. Porteous CM, Logan A, Evans C, et al. Rapid uptake of lipophilic triphenylphosphonium cations by mitochondria *in vivo* following intravenous injection: implications for mitochondria-specific therapies and probes. *Biochim Biophys Acta*. 2010; 1800(9):1009–1017. [PubMed: 20621583]
237. Murphy MP, Echtay KS, Blaikie FH, et al. Superoxide activates uncoupling proteins by generating carbon-centered radicals and initiating lipid peroxidation: studies using a mitochondria-targeted spin trap derived from alpha-phenyl-*N-tert*-butylnitron. *J Biol Chem*. 2003; 278(49):48534–48545. [PubMed: 12972420]
238. Hardy M, Chalier F, Ouari O, et al. Mito-DEPMPO synthesized from a novel NH₂-reactive DEPMPO spin trap: a new and improved trap for the detection of superoxide. *Chem Commun*. 2007; (10):1083–1085.
239. Quin C, Trnka J, Hay A, Murphy MP, Hartley RC. Synthesis of a mitochondria-targeted spin trap using a novel Parham-type cyclization. *Tetrahedron*. 2009; 65(39):8154–8160. [PubMed: 19888470]
240. Robertson L, Hartley RC. Synthesis of *N*-arylpyridinium salts bearing a nitron spin trap as potential mitochondria-targeted antioxidants. *Tetrahedron*. 2009; 65(27):5284–5292. [PubMed: 19693262]
241. Janzen EG, Dudley RL, Shetty RV. Synthesis and electron spin resonance chemistry of nitronyl labels for spin trapping. α -phenyl *N*-[5-(5-methyl-2,2-dialkyl-1,3-dioxanyl)] nitrones and α -(*N*-alkylpyridinium) *N*-(*tert*-butyl) nitrones. *J Am Chem Soc*. 1979; 101:243–245.
242. Sar CP, Hideg E, Vass I, Hideg K. Synthesis of alpha-aryl *N*-adamant-1-yl nitrones and using them for spin trapping of hydroxyl radicals. *Bioorg Med Chem Lett*. 1998; 8(4):379–384. [PubMed: 9871689]
243. Bienert GP, Schjoerring JK, Jahn TP. Membrane transport of hydrogen peroxide. *Biochim Biophys Acta*. 2006; 1758(8):994–1003. [PubMed: 16566894]
244. Folmer V, Pedroso N, Matias AC, et al. H₂O₂ induces rapid biophysical and permeability changes in the plasma membrane of *Saccharomyces cerevisiae*. *Biochim Biophys Acta*. 2008; 1778(4):1141–1147. [PubMed: 18187036]
245. Stein, WD. Channels, Carriers, and Pumps: An Introduction to Membrane Transport. Academic Press; San Francisco, CA, USA: 1990.
246. Tsai P, Elas M, Parasca AD, et al. 5-carboxy-5-methyl-1-pyrroline *N*-oxide: a spin trap for the hydroxyl radical. *J Chem Soc Perkin Trans*. 2001; 2:875–880.
247. Durand G, Prosa RA, Han Y, et al. Spin trapping and cytoprotective properties of fluorinated amphiphilic carrier conjugates of cyclic versus linear nitrones. *Chem Res Toxicol*. 2009; 22(9):1570–1581. Nitron cytoprotection is dependent on nitron structure and type of oxidant. [PubMed: 19678661]
248. Poeggeler B, Durand G, Polidori A, et al. Mitochondrial medicine: neuroprotection and life extension by the new amphiphilic nitron LPBNAH acting as a highly potent antioxidant agent. *J Neurochem*. 2005; 95(4):962–973. [PubMed: 16135084]

249. Tanguy S, Durand G, Reboul C, et al. Protection against reactive oxygen species injuries in rat isolated perfused hearts: effect of LPBNAH, a new amphiphilic spin-trap derived from PBN. *Cardiovasc Drugs Ther.* 2006; 20(2):147–149. [PubMed: 16534547]
250. Durand G, Polidori A, Ouari O, et al. Synthesis and preliminary biological evaluations of ionic and nonionic amphiphilic alpha-phenyl-*N-tert*-butylnitron derivatives. *J Med Chem.* 2003; 46(24):5230–5237. [PubMed: 14613325]
251. Durand G, Polidori A, Salles J-P, Pucci B. Synthesis of a new family of glycolipidic nitrones as potential antioxidant drugs for neurodegenerative disorders. *Bioorg Med Chem Lett.* 2003; 13(5): 859–862. [PubMed: 12617908]
252. Durand G, Poeggeler B, Ortial S, et al. Amphiphilic amide nitrones: a new class of protective agents acting as modifiers of mitochondrial metabolism. *J Med Chem.* 2010; 53(13):4849–4861. [PubMed: 20527971]
253. Chalier F, Ouari O, Tordo P. ESR study of spin-trapping with two glycosylated analogues of PBN able to target cell membrane lectins. *Org Biomol Chem.* 2004; 2(6):927–934. [PubMed: 15007424]
254. Liu Y, Song Y, Du L, et al. Novel glutathione-linked nitrones as dual free radical probes. *New J Chem.* 2011; 35:1485–1490.
255. Liu YP, Ji YQ, Song YG, et al. A novel spin trap for targeting sulfhydryl-containing polypeptides. *Chem Commun.* 2005; 39:4943–4945.
256. Lardinois OM, Chatterjee S, Mason RP, Tomer KB, Deterding LJ. Biotinylated analogue of the spin-trap 5,5-dimethyl-1-pyrroline-*N*-oxide for the detection of low-abundance protein radicals by mass spectrometry. *Anal Chem.* 2010; 82(22):9155–9158. [PubMed: 20957988]
257. Karoui H, Clement J-L, Rockenbauer A, Siri D, Tordo P. Synthesis and structure of 5,5-diethoxycarbonyl-1-pyrroline *N*-oxide (DECPO). Application to superoxide radical trapping. *Tetra Lett.* 2004; 45(1):149–152.
258. Hardy M, Bardelang D, Karoui H, et al. Improving the trapping of superoxide radical with a betacyclodextrin-5-diethoxyphosphoryl-5-methyl-1-pyrroline-*N*-oxide (DEPMPO) conjugate. *Chem Eur J.* 2009; 15(42):11114–11118. [PubMed: 19760720]
259. Durand G, Poeggeler B, Boeker J, et al. Fine-tuning the amphiphilicity: a crucial parameter in the design of potent alpha-phenyl-*N-tert*-butylnitron analogues. *J Med Chem.* 2007; 50(17):3976–3979. [PubMed: 17649989]
260. Kim SU, Villamena FA. Reactivities of superoxide and hydroperoxyl radicals with disubstituted cyclic nitrones: a DFT study. *J Phys Chem A.* 2012; 116(2):886–898. [PubMed: 22085265]
261. Villamena FA, Horak V, Crist DR. Cyclic voltammetry of metal complexes of nitrones and nitroxides. *Inorg Chim Acta.* 2003; 342:125–130.
262. McIntire GL, Blount HN, Stronks HJ, Shetty RV, Janzen EG. Spin trapping in electrochemistry. 2. Aqueous and nonaqueous electrochemical characterizations of spin traps. *J Phys Chem.* 1980; 84:916–921.
263. Haseloff RF, Mertsch K, Rohde E, Baeger I, Grigor'ev IA, Blasig IE. Cytotoxicity of spin trapping compounds. *FEBS Lett.* 1997; 418(1–2):73–75. [PubMed: 9414098]
264. Khan N, Wilmot CM, Rosen GM, et al. Spin traps: *in vitro* toxicity and stability of radical adducts. *Free Radic Biol Med.* 2003; 34(11):1473–1481. [PubMed: 12757857]
265. Rohr-Udilova N, Stolze K, Marian B, Nohl H. Cytotoxicity of novel derivatives of the spin trap EMPO. *Bioorg Med Chem Lett.* 2006; 16(3):541–546. [PubMed: 16289821]
266. Novelli GP, Angiolini P, Tani R, Consales G, Bordini L. Phenyl-T-butyl-nitron is active against traumatic shock in rats. *Free Radic Res Commun.* 1986; 1(5):321–327. [PubMed: 3505231]
267. Ley JJ, Prado R, Wei JQ, Bishopric NH, Becker DA, Ginsberg MD. Neuroprotective antioxidant STAZN protects against myocardial ischemia/reperfusion injury. *Biochem Pharmacol.* 2008; 75(2):448–456. [PubMed: 17936251]
268. Dias AG, Santos CE, Cyrino FZ, Bouskela E, Costa PR. *N-tert*-butyl and *N*-methyl nitrones derived from aromatic aldehydes inhibit macromolecular permeability increase induced by ischemia/reperfusion in hamsters. *Bioorg Med Chem.* 2009; 17(11):3995–3998. [PubMed: 19410467]

269. Xu K, Puchowicz MA, Sun X, LaManna JC. Decreased brainstem function following cardiac arrest and resuscitation in aged rat. *Brain Res.* 2010; 1328:181–189. [PubMed: 20211610]
270. Windelborn JA, Lipton P. Lysosomal release of cathepsins causes ischemic damage in the rat hippocampal slice and depends on NMDA-mediated calcium influx, arachidonic acid metabolism, and free radical production. *J Neurochem.* 2008; 106(1):56–69. [PubMed: 18363826]
271. Tawadros PS, Powers KA, Yang I, et al. Stilbazulenyl nitron decreases oxidative stress and reduces lung injury after hemorrhagic shock/resuscitation and LPS. *Antioxid Redox Signal.* 2007; 9(11):1971–1977. [PubMed: 17715998]
272. Samadi A, Soriano E, Revuelta J, et al. Synthesis, structure, theoretical and experimental *in vitro* antioxidant/pharmacological properties of alpha-aryl, *N*-alkyl nitrones, as potential agents for the treatment of cerebral ischemia. *Bioorg Med Chem.* 2011; 19(2):951–960. [PubMed: 21190861]
273. Sun Y, Jiang J, Zhang Z, et al. Antioxidative and thrombolytic TMP nitron for treatment of ischemic stroke. *Bioorg Med Chem.* 2008; 16(19):8868–8874. [PubMed: 18790647]
274. Green AR. Protecting the brain: the search for a clinically effective neuroprotective drug for stroke. *Crit Rev Neurobiol.* 2004; 16(1&2):91–97. [PubMed: 15581404]
275. Floyd RA, Hensley K, Bing G. Evidence for enhanced neuro-inflammatory processes in neurodegenerative diseases and the action of nitrones as potential therapeutics. *Adv Res Neurodegener.* 2000; 8:387–414.
276. Kamat CD, Gadal S, Mhatre M, Williamson KS, Pye QN, Hensley K. Antioxidants in central nervous system diseases: preclinical promise and translational challenges. *J Alzheimers Dis.* 2008; 15(3):473–493. [PubMed: 18997301]
277. Floyd RA, Towner RA, Wu D, et al. Anti-cancer activity of nitrones in the Apc(Min/+) model of colorectal cancer. *Free Radic Res.* 2010; 44(1):108–117. [PubMed: 19886748]
278. Asanuma T, Doblas S, Tesiram YA, et al. Visualization of the protective ability of a free radical trapping compound against rat C6 and F98 gliomas with diffusion tensor fiber tractography. *J Magn Reson Imaging.* 2008; 28(3):574–587. [PubMed: 18777527]
279. Sklavounou E, Hay A, Ashraf N, et al. The use of telomere biology to identify and develop superior nitron based anti-oxidants. *Biochem Biophys Res Commun.* 2006; 347(2):420–427. [PubMed: 16828709]
280. Choteau F, Durand G, Ranchon-Cole I, Cercy C, Pucci B. Cholesterol-based alpha-phenyl-*N*-*tert*-butyl nitron derivatives as antioxidants against light-induced retinal degeneration. *Bioorg Med Chem Lett.* 2010; 20(24):7405–7409. [PubMed: 21071218]
281. Ewert DL, Lu J, Li W, Du X, Floyd R, Kopke R. Antioxidant treatment reduces blast-induced cochlear damage and hearing loss. *Hear Res.* 2012; 285(1–2):29–39. [PubMed: 22326291]
282. Floyd RA. Serendipitous findings while researching oxygen free radicals. *Free Radic Biol Med.* 2009; 46(8):1004–1013. [PubMed: 19439210]
283. Choi CH, Chen K, Vasquez-Weldon A, Jackson RL, Floyd RA, Kopke RD. Effectiveness of 4-hydroxy phenyl *N*-*tert*-butylnitron (4-OHPBN) alone and in combination with other antioxidant drugs in the treatment of acute acoustic trauma in chinchilla. *Free Radic Biol Med.* 2008; 44(9):1772–1784. [PubMed: 18328271]
284. Zweier JL, Kuppusamy P, Lutty GA. Measurement of endothelial cell free radical generation: evidence for a central mechanism of free radical injury in postischemic tissues. *Proc Natl Acad Sci USA.* 1988; 85(11):4046–4050. [PubMed: 2836868]
285. Chen YR, Chen CL, Pfeiffer DR, Zweier JL. Mitochondrial complex II in the post-ischemic heart: oxidative injury and the role of protein *S*-glutathionylation. *J Biol Chem.* 2007; 282(45):32640–32654. [PubMed: 17848555]
286. Brandes RP, Weissmann N, Schroder K. NADPH oxidases in cardiovascular disease. *Free Radic Biol Med.* 2010; 49(5):687–706. [PubMed: 20444433]
287. Baudry N, Laemmel E, Vicaute E. *In vivo* reactive oxygen species production induced by ischemia in muscle arterioles of mice: involvement of xanthine oxidase and mitochondria. *Am J Physiol Heart Circ Physiol.* 2008; 294(2):H821–828. [PubMed: 18055522]
288. Otani H. The role of nitric oxide in myocardial repair and remodeling. *Antioxid Redox Signal.* 2009; 11(8):1913–1928. [PubMed: 19203224]

289. Bertuglia S, Giusti A. Microvascular oxygenation and oxidative stress during postischemic reperfusion. PO₂, ROS, and NO during reperfusion. *Adv Exp Med Biol.* 2005; 566:23–29. [PubMed: 16594130]
290. Tosaki A, Blasig IE, Pali T, Ebert B. Heart protection and radical trapping by DMPO during reperfusion in isolated working rat hearts. *Free Radic Biol Med.* 1990; 8(4):363–372. [PubMed: 2165975]
291. Tosaki A, Braquet P. DMPO and reperfusion injury: arrhythmia, heart function, electron spin resonance, and nuclear magnetic resonance studies in isolated working guinea pig hearts. *Am Heart J.* 1990; 120(4):819–830. [PubMed: 2171311]
292. Bradamante S, Monti E, Paracchini L, Lazzarini E, Piccinini F. Protective activity of the spin trap *tert*-butyl- α -phenyl nitron (PBN) in reperfused rat heart. *J Mol Cell Cardiol.* 1992; 24(4):375–386. [PubMed: 1619668]
293. Vergely C, Tabard A, Maupoil V, Rochette L. Isolated perfused rat hearts release secondary free radicals during ischemia reperfusion injury: cardiovascular effects of the spin trap α -phenyl *N*-*tert*-butylnitron. *Free Radic Res.* 2001; 35(5):475–489. [PubMed: 11767406]
294. Paradies G, Petrosillo G, Pistolesi M, Ruggiero FM. Reactive oxygen species generated by the mitochondrial respiratory chain affect the complex III activity via cardiolipin peroxidation in beef-heart submitochondrial particles. *Mitochondrion.* 2001; 1(2):151–159. [PubMed: 16120275]
295. McLeod CJ, Pagel I, Sack MN. The mitochondrial biogenesis regulatory program in cardiac adaptation to ischemia – a putative target for therapeutic intervention. *Trends Cardiovasc Med.* 2005; 15(3):118–123. [PubMed: 16039972]
296. Nisoli E, Clementi E, Paolucci C, et al. Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. *Science.* 2003; 299(5608):896–899. [PubMed: 12574632]
297. Cruickshanks KJ, Klein R, Klein BE. Sunlight and age-related macular degeneration. The Beaver Dam Eye Study. *Arch Ophthalmol.* 1993; 111(4):514–518. [PubMed: 8470986]
298. Cideciyan AV, Hood DC, Huang Y, et al. Disease sequence from mutant rhodopsin allele to rod and cone photoreceptor degeneration in man. *Proc Natl Acad Sci USA.* 1998; 95(12):7103–7108. [PubMed: 9618546]
299. Organisciak DT, Vaughan DK. Retinal light damage: mechanisms and protection. *Prog Retin Eye Res.* 2010; 29(2):113–134. [PubMed: 19951742]
300. Wenzel A, Grimm C, Marti A, et al. *c-fos* controls the “private pathway” of light-induced apoptosis of retinal photoreceptors. *J Neurosci.* 2000; 20(1):81–88. [PubMed: 10627584]
301. Demontis GC, Longoni B, Marchiafava PL. Molecular steps involved in light-induced oxidative damage to retinal rods. *Invest Ophthalmol Vis Sci.* 2002; 43(7):2421–2427. [PubMed: 12091446]
302. Komeima K, Rogers BS, Campochiaro PA. Antioxidants slow photoreceptor cell death in mouse models of retinitis pigmentosa. *J Cell Physiol.* 2007; 213(3):809–815. [PubMed: 17520694]
303. Komeima K, Rogers BS, Lu L, Campochiaro PA. Antioxidants reduce cone cell death in a model of retinitis pigmentosa. *Proc Natl Acad Sci USA.* 2006; 103(30):11300–11305. [PubMed: 16849425]
304. Nakazawa T, Hisatomi T, Nakazawa C, et al. Monocyte chemoattractant protein 1 mediates retinal detachment-induced photoreceptor apoptosis. *Proc Natl Acad Sci USA.* 2007; 104(7):2425–2430. [PubMed: 17284607]
305. Yang JH, Basinger SF, Gross RL, Wu SM. Blue light-induced generation of reactive oxygen species in photoreceptor ellipsoids requires mitochondrial electron transport. *Invest Ophthalmol Vis Sci.* 2003; 44(3):1312–1319. [PubMed: 12601064]
306. Osborne NN, Li GY, Ji D, Mortiboys HJ, Jackson S. Light affects mitochondria to cause apoptosis to cultured cells: possible relevance to ganglion cell death in certain optic neuropathies. *J Neurochem.* 2008; 105(5):2013–2028. [PubMed: 18315568]
307. Nakajima Y, Inokuchi Y, Nishi M, Shimazawa M, Otsubo K, Hara H. Coenzyme Q10 protects retinal cells against oxidative stress *in vitro* and *in vivo*. *Brain Res.* 2008; 1226:226–233. [PubMed: 18598676]
308. Fu Y, Tang M, Fan Y, Zou H, Sun X, Xu X. Anti-apoptotic effects of melatonin in retinal pigment epithelial cells. *Front Biosci.* 2012; 17:1461–1468.

309. Tanito M, Masutani H, Kim YC, Nishikawa M, Ohira A, Yodoi J. Sulforaphane induces thioredoxin through the antioxidant-responsive element and attenuates retinal light damage in mice. *Invest Ophthalmol Vis Sci.* 2005; 46(3):979–987. [PubMed: 15728556]
310. Feng Z, Liu Z, Li X, et al. alpha-tocopherol is an effective Phase II enzyme inducer: protective effects on acrolein-induced oxidative stress and mitochondrial dysfunction in human retinal pigment epithelial cells. *J Nutr Biochem.* 2010; 21(12):1222–1231. [PubMed: 20153624]
311. Chen B, Tang L. Protective effects of catalase on retinal ischemia/reperfusion injury in rats. *Exp Eye Res.* 2011; 93(5):599–606. [PubMed: 21824472]
312. Liu Y, Tang L, Chen B. Effects of antioxidant gene therapy on retinal neurons and oxidative stress in a model of retinal ischemia/reperfusion. *Free Radic Biol Med.* 2012; 52(5):909–915. [PubMed: 22240151]
313. Ranchon I, Chen S, Alvarez K, Anderson RE. Systemic administration of phenyl-*N-tert*-butylnitronone protects the retina from light damage. *Invest Ophthalmol Vis Sci.* 2001; 42(6):1375–1379. [PubMed: 11328754]
314. Tomita H, Kotake Y, Anderson RE. Mechanism of protection from light-induced retinal degeneration by the synthetic antioxidant phenyl-*N-tert*-butylnitronone. *Invest Ophthalmol Vis Sci.* 2005; 46(2):427–434. [PubMed: 15671265]
315. Reme CE, Grimm C, Hafezi F, Wenzel A, Williams TP. Apoptosis in the retina: the silent death of vision. *News Physiol Sci.* 2000; 15:120–124. [PubMed: 11390893]
316. Hafezi F, Steinbach JP, Marti A, et al. The absence of c-fos prevents light-induced apoptotic cell death of photoreceptors in retinal degeneration *in vivo*. *Nat Med.* 1997; 3(3):346–349. [PubMed: 9055866]
317. Hafezi F, Grimm C, Wenzel A, Abegg M, Yaniv M, Reme CE. Retinal photoreceptors are apoptosis-competent in the absence of JunD/AP-1. *Cell Death Differ.* 1999; 6(10):934–936. [PubMed: 10617374]
318. Grimm C, Wenzel A, Behrens A, Hafezi F, Wagner EF, Reme CE. AP-1 mediated retinal photoreceptor apoptosis is independent of *N*-terminal phosphorylation of c-Jun. *Cell Death Differ.* 2001; 8(8):859–867. [PubMed: 11526439]
319. Nir I, Agarwal N. Diurnal expression of c-fos in the mouse retina. *Brain Res Mol Brain Res.* 1993; 19(1–2):47–54. [PubMed: 7689683]
320. Grimm C, Wenzel A, Hafezi F, Yu S, Redmond TM, Reme CE. Protection of Rpe65-deficient mice identifies rhodopsin as a mediator of light-induced retinal degeneration. *Nat Genet.* 2000; 25(1):63–66. [PubMed: 10802658]
321. Gollapalli DR, Maiti P, Rando RR. RPE65 operates in the vertebrate visual cycle by stereospecifically binding all-trans-retinyl esters. *Biochemistry.* 2003; 42(40):11824–11830. [PubMed: 14529294]
322. Mata NL, Moghrabi WN, Lee JS, et al. Rpe65 is a retinyl ester binding protein that presents insoluble substrate to the isomerase in retinal pigment epithelial cells. *J Biol Chem.* 2004; 279(1):635–643. [PubMed: 14532273]
323. Lamb TD, Pugh EN Jr. Dark adaptation and the retinoid cycle of vision. *Prog Retin Eye Res.* 2004; 23(3):307–380. [PubMed: 15177205]
324. Noell WK, Walker VS, Kang BS, Berman S. Retinal damage by light in rats. *Invest Ophthalmol.* 1966; 5(5):450–473. [PubMed: 5929286]
325. Kaitz M, Auerbach E. Action spectrum for light-induced retinal degeneration in dystrophic rats. *Vision Res.* 1979; 19(9):1041–1044. [PubMed: 532117]
326. Konovalova TA, Kispert LD, Polyakov NE, Leshina TV. EPR spin trapping detection of carbon-centered carotenoid and beta-ionone radicals. *Free Radic Biol Med.* 2000; 28(7):1030–1038. [PubMed: 10832064]
327. Poliakov E, Parikh T, Ayele M, et al. Aromatic lipophilic spin traps effectively inhibit RPE65 isomerohydrolase activity. *Biochemistry.* 2011; 50(32):6739–6741. [PubMed: 21736383]
328. Doblas S, Saunders D, Kshirsagar P, et al. Phenyl-*tert*-butylnitronone induces tumor regression and decreases angiogenesis in a C6 rat glioma model. *Free Radic Biol Med.* 2008; 44(1):63–72. [PubMed: 18045548]

329. Floyd RA, Kotake Y, Hensley K, Nakae D, Konishi Y. Reactive oxygen species in choline deficiency induced carcinogenesis and nitron inhibition. *Mol Cell Biochem.* 2002; 234–235(1–2):195–203.
330. Nakae D, Uematsu F, Kishida H, et al. Inhibition of the development of hepatocellular carcinomas by phenyl *N-tert*-butyl nitron in rats fed with a choline-deficient, l-amino acid-defined diet. *Cancer Lett.* 2004; 206(1):1–13. [PubMed: 15019154]
331. Nakae D, Kotake Y, Kishida H, et al. Inhibition by phenyl *N-tert*-butyl nitron of early phase carcinogenesis in the livers of rats fed a choline-deficient, l-amino acid-defined diet. *Cancer Res.* 1998; 58(20):4548–4551. [PubMed: 9788598]
332. Aoki K, Taketo MM. Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene. *J Cell Sci.* 2007; 120(Part 19):3327–3335. [PubMed: 17881494]
333. Haigis KM, Hoff PD, White A, Shoemaker AR, Halberg RB, Dove WF. Tumor regionality in the mouse intestine reflects the mechanism of loss of Apc function. *Proc Natl Acad Sci USA.* 2004; 101(26):9769–9773. [PubMed: 15210940]
334. Moser AR, Dove WF, Roth KA, Gordon JL. The Min (multiple intestinal neoplasia) mutation: its effect on gut epithelial cell differentiation and interaction with a modifier system. *J Cell Biol.* 1992; 116(6):1517–1526. [PubMed: 1541640]
335. Luqman S, Pezzuto JM. NF- κ B: a promising target for natural products in cancer chemoprevention. *Phytother Res.* 2010; 24(7):949–963. [PubMed: 20577970]
336. Cerella C, Sobolewski C, Dicato M, Diederich M. Targeting COX-2 expression by natural compounds: a promising alternative strategy to synthetic COX-2 inhibitors for cancer chemoprevention and therapy. *Biochem Pharmacol.* 2010; 80(12):1801–1815. [PubMed: 20615394]
337. Yang G-Y, Taboada S, Liao J. Induced nitric oxide synthase as a major player in the oncogenic transformation of inflamed tissue. *Methods Mol Biol.* 2009; 512(2):119–156. [PubMed: 19347276]
338. Kotake Y, Sang H, Miyajima T, Wallis GL. Inhibition of NF-kappaB, iNOS mRNA, COX2 mRNA, and COX catalytic activity by phenyl-*N-tert*-butylnitron (PBN). *Biochim Biophys Acta.* 1998; 1448(1):77–84. [PubMed: 9824673]
339. Zhai Z, Gomez-Mejiba SE, Zhu H, Lupu F, Ramirez DC. The spin trap 5,5-dimethyl-1-pyrroline *N*-oxide inhibits lipopolysaccharide-induced inflammatory response in RAW 264.7 cells. *Life Sci.* 2012; 90(11–12):432–439. [PubMed: 22285597]
340. Hakumaki JM, Poptani H, Sandmair AM, Yla-Herttuala S, Kauppinen RA. ^1H MRS detects polyunsaturated fatty acid accumulation during gene therapy of glioma: implications for the *in vivo* detection of apoptosis. *Nat Med.* 1999; 5(11):1323–1327. [PubMed: 10546002]
341. Preul MC, Caramanos Z, Villemure JG, et al. Using proton magnetic resonance spectroscopic imaging to predict *in vivo* the response of recurrent malignant gliomas to tamoxifen chemotherapy. *Neurosurgery.* 2000; 46(2):306–318. [PubMed: 10690719]
342. Kubik S. Anion recognition in water. *Chem Soc Rev.* 2010; 39:3648–3663. [PubMed: 20617241]
343. Firuzi O, Miri R, Tavakkoli M, Saso L. Antioxidant therapy: current status and future prospects. *Curr Med Chem.* 2011; 18(25):3871–3888. [PubMed: 21824100]
344. Ziolo MT, Bers DM. The real estate of NOS signaling: location, location, location. *Circ Res.* 2003; 92(12):1279–1281. [PubMed: 12829613]
345. Xia Y, Tsai A-L, Berka V, Zweier JL. Superoxide generation from endothelial nitric-oxide synthase. A Ca^{2+} /calmodulin-dependent and tetrahydrobiopterin regulatory process. *J Biol Chem.* 1998; 273(40):25804–25808. [PubMed: 9748253]
346. Raffaella R, Sandra C, Antonella DS, Anna F, Gianni L, Pasquale P. A lipophilic nitric oxide-donor and a lipophilic antioxidant compound protect rat heart against ischemia-reperfusion injury if given as hybrid molecule but not as a mixture. *J Cardiovasc Pharmacol.* 2012; 59(3):241–248. [PubMed: 22030894]
347. Kim SH, Kim SH, Choi M, et al. Natural therapeutic magnesium lithospermate B potentially protects the endothelium from hyperglycaemia-induced dysfunction. *Cardiovasc Res.* 2010; 87(4):713–722. [PubMed: 20299332]

348. Das A, Gopalakrishnan B, Voss OH, Doseff AI, Villamena FA. Inhibition of ROS-induced apoptosis in endothelial cells by nitron spin traps via induction of phase II enzymes and suppression of mitochondrial-dependent pro-apoptotic signaling. *Biochem Pharmacol.* 2012 Epub ahead of print.
349. Pastore A, Piemonte F. *S*-glutathionylation signaling in cell biology: progress and prospects. *Eur J Pharm Sci.* 2012 In Press.
350. Aracena P, Tang W, Hamilton SL, Hidalgo C. Effects of *S*-glutathionylation and *S*-nitrosylation on calmodulin binding to triads and FKBP12 binding to type 1 calcium release channels. *Antioxid Redox Signal.* 2005; 7:870–881. [PubMed: 15998242]
351. Lock JT, Sinkins WG, Schilling WP. Effect of protein *S*-glutathionylation on Ca^{2+} homeostasis in cultured aortic endothelial cells. *Am J Physiol Heart Circ Physiol.* 2011; 300:H493–H506. [PubMed: 21148766]
352. Hurd TR, Costa NJ, Dahm CC, et al. Glutathionylation of mitochondrial proteins. *Antioxid Redox Signaling.* 2005; 7–8:999–1010.
353. Chen C-A, Wang T-Y, Varadharaj S, et al. *S*-glutathionylation uncouples eNOS and regulates its cellular and vascular function. *Nature.* 2010; 468:1115–1118. [PubMed: 21179168]
354. Stoyanovsky DA, Goldman R, Jonnalagadda SS, Day BW, Claycamp HG, Kagan VE. Detection and characterization of the electron paramagnetic resonance-silent glutathionyl-5,5-dimethyl-1-pyrroline *N*-oxide adduct derived from redox cycling of phenoxyl radicals in model systems and HL-60 cells. *Arch Biochem Biophys.* 1996; 330:3–11. [PubMed: 8651701]
355. Polovyanenko DN, Plyusnin VF, Reznikov VA, Khramtsov VV, Bagryanskaya EG. Mechanistic studies of the reactions of nitron spin trap PBN with glutathyl radical. *J Phys Chem B.* 2008; 112:4841–4847. [PubMed: 18363401]
356. Jiang Z, Hu Z, Zeng L, et al. The role of the Golgi apparatus in oxidative stress: is this organelle less significant than mitochondria? *Free Radic Biol Med.* 2011; 50(8):907–917. [PubMed: 21241794]
357. Jellinger KA. Basic mechanisms of neurodegeneration: a critical update. *J Cell Mol Med.* 2010; 14(3):457–487. [PubMed: 20070435]
358. Gregersen N, Bross P. Protein misfolding and cellular stress: an overview. *Methods Mol Biol.* 2010; 648:3–23. [PubMed: 20700702]
359. Minamino T, Kitakaze M. ER stress in cardiovascular disease. *J Mol Cell Cardiol.* 2010; 48(6): 1105–1110. [PubMed: 19913545]
360. Fulton D, Babbitt R, Zoellner S, et al. Targeting of endothelial nitric-oxide synthase to the cytoplasmic face of the Golgi complex or plasma membrane regulates Akt- versus calcium-dependent mechanisms for nitric oxide release. *J Biol Chem.* 2004; 279(29):30349–30357. [PubMed: 15136572]
361. Janib SM, Moses AS, MacKay JA. Imaging and drug delivery using theranostic nanoparticles. *Adv Drug Deliv Rev.* 2010; 62(11):1052–1063. [PubMed: 20709124]

Glossary

Reactive oxygen species/reactive nitrogen species

Examples of radical reactive oxygen species are $\text{O}_2^{\bullet-}/\text{HO}_2^{\bullet}$, $\text{HO}^{\bullet}$, $\text{RO}_2^{\bullet}$, $\text{RO}^{\bullet}$, $\text{CO}_3^{\bullet-}$ and $\text{CO}_2^{\bullet-}$; nonradicals include: H_2O_2 , HOCl , O_3 , O_2^1 g and ROOH ; while examples of reactive nitrogen species are NO , ONOO^- , $^{\bullet}\text{NO}_2$ or ROONO .

Oxidative stress

Biological imbalance between the pro-oxidant generation and antioxidant repair mechanisms in favor of the former.

Antioxidant therapy

Pharmacological strategy to suppress minimize or reverse oxidative stress through direct sequestration of reactive species, induction of antioxidant enzymes expression or activity, suppression of signal transduction or gene induction leading to apoptosis, and reversal or suppression of pro-oxidative enzyme activity, among others.

NXY-059

Disulfonyl derivative of α -phenyl-*tert*-butyl nitron. Was under development for the treatment of acute stroke by AstraZeneca and was the first nitron-based compound to reach the SAINT-1 Phase III clinical trials.

DMPO

First synthesized by Sir Alexander Todd, 1957 Nobel laureate in chemistry, as a model compound to investigate the corrin nucleus of vitamin B12. Iwamura and Inamoto in 1967 first demonstrated the spin trapping of C-centered radicals by 5,5-dimethyl-1-pyrroline *N*-oxide, and Janzen coined the word spin trapping in 1968.

Executive summary

Innovative spin-trap design

- Spin-trap development requires incorporation into one molecular design of the three major required qualities that are still lacking from the currently used nitrones; that is, high rate constant for $O_2^{\bullet-}$ trapping, biostable spin adduct and target specific.
- Using computational chemistry, rational design of spin traps can be achieved. Advancements in spin-trap development over the past few years had focused on increasing spin trap reactivity to $O_2^{\bullet-}$ by exploiting the electron-withdrawing ability of amide substituents, as well as its interaction with the $O_2^{\bullet-}$ via α -effect.
- Spin adducts with extraordinary stability can be achieved through nitron conjugation with cyclodextrin or anion receptors such as calixpyrroles.
- Subcellular specificity of nitrones can be realized via bi-conjugation with target-specific groups.

Nitron chemical properties

- Nitrones react with a variety of reactive oxygen, nitrogen and sulfur species, as well as nucleophiles that are implicated in the initiation of oxidative damage to key biomolecular systems.
- Nitrones (conjugate acid $pK_a = 6.0$ versus pK_a for $HO_2^{\bullet}/O_2^{\bullet-} = 4.8$) react more efficiently under slight acidic pH than in neutral pH to $O_2^{\bullet-}$, which is relevant in acidosis condition such as in ischemic and cancer cells.
- Cyclic nitrones (e.g., 5,5-dimethyl-1-pyrroline *N*-oxide) react to $O_2^{\bullet-}$ and $HO_2^{\bullet}$ faster than the linear nitrones such as α -phenyl-tert-butyl nitron.
- The first example of an antioxidant that can convert reactive oxygen species to more beneficial radicals such as NO. Nitron $O_2^{\bullet-}$ adducts decompose to yield NO, thereby making them controlled delivery systems for NO as a function of reactive oxygen species generation.

Nitron biological properties

- Nitrones have been applied in both *in vitro* and *in vivo* systems as therapeutic agents against cardiovascular disease, neurodegeneration (which includes ocular damage) and

- cancer. Other than their spin-trapping ability, the exact mechanisms of their protection is not clear.
- *In vitro* studies show that nitronone protection against various types of oxidant is dependent on nitronone structure.
- Nitronone pharmacological activity was found to be due partly to salvaging the mitochondrial electron transport chain, increasing mitochondrial biogenesis, activation of transcription factors and downregulation of modulators of inflammation such as NF- κ B, Cox-2 and *n*NOS.
- Preliminary evidence in our laboratory shows that nitrones can bolster antioxidant enzymes activity (e.g., SOD, catalase, heme oxygenase and glutathione reductase) via Nrf-2 nuclear translocation, increase glutathione levels, improve contractile function of the *nNOS*^{-/-} knockout myocytes, inhibit caspase-3 activation and reverse eNOS inactivation.

Figure 1. Analogy between carbonyl compounds and nitrones showing the electropositive α -carbon

Figure 2. Formation of aminoxyl spin adduct from nitrones

Figure 3. Common cyclic and linear nitrones

Figure 4. Formation of reactive species from $O_2^{\bullet-}$

Figure 5. Electron paramagnetic resonance spectroscopic techniques for the detection of $\text{O}_2^{\bullet-}$. Detection of $\text{O}_2^{\bullet-}$ using **(A)** spin-formation and **(B)** spin-scavenging methods.

Figure 6. Reaction of a nitron with a free radical

Figure 7. The electron paramagnetic resonance spin-trapping process
Showing the formation of a unique spectral profile of (A) the DMPO-OH and (B) DMPO-OOH adducts.

Figure 8. DMPO type nitrones used as models for the theoretical investigation of spin trapping of superoxide radical

Reproduced with permission from [127] © American Chemical Society.

Figure 9. Nitronyl-C (C-2) charge densities

Correlation of the nitronyl-C (C-2) charge densities with that of the (A) free energies (G_{rxn-1} , 298K, kcal/mol) ($r^2 = 0.78$) and (B) rate constants ($\log k_{rxn-1}$) of $O_2^{\bullet-}$ addition to nitrones in the aqueous phase at the Polarizable Continuum Model (water)/mPW1K/6-31+G(d,p) level of theory at 298 K ($r^2 = 0.76$, excluding the outliers DEPMPO and DIMAPO). Shows the degree of correlation between k_{rxn-1} and G_{rxn-1} at the same level of theory with $r^2 = 0.73$ excluding the outliers DIMAPO and DEPO).

Reproduced with permission from [127] © American Chemical Society.

Figure 10. Perturbation on the spin and charge density distribution on the superoxide radical upon hydrogen bonding with MCCP and AMPO showing intermediate electronic distribution between superoxide and hydroperoxyl radicals

Figure 11. Improved spin trapping of $\text{O}_2^{\bullet -}$ using calixpyrrole conjugated to DMPO
Reproduced with permission from [133] © American Chemical Society.

Figure 12. Suggested mechanisms and free energies ($G_{298K,aq}$ in kcal/mol) of $O_2^{\bullet-}/HO_2^{\bullet}$ addition to a nitronium at the Polarizable Continuum Model (water)/B3LYP/6-31+G(d,p)//B3LYP/6-31G(d) level of theory

Figure 13. Nucleophilic addition/oxidation (Forrester–Hepburn) mechanism for the formation of radical adduct

SR: Sarcoplasmic reticulum.

Figure 14. Examples of tetra-alkyl-β-substituted nitroxides, TEMPO and PROXYL, showing the reversibility of their redox behavior and superoxide dismutase mimetic property

Figure 15. Superoxide radical adduct of DMPO showing the irreversibility of its reduction and oxidation leading to the formation of various biologically relevant by-products
Reproduced with permission from [187] © American Chemical Society.

Figure 16. Redox reaction of $\text{O}_2^{\bullet-}$ with superoxide radical adduct of DMPO leading to the formation of various products

Figure 17. Mechanism of decomposition of superoxide radical adduct of DMPO under basic conditions

Figure 18. Unimolecular decomposition of the hydroperoxyl adduct of nitrones
Reproduced with permission from [202] © American Chemical Society.

Figure 19. X-band electron paramagnetic resonance spectra of NOFe(MGD)₂ complex
Spectra resulting from purging DMPO solution containing (A) phorbolmyristate acetate-activated human neutrophils at pH 6.7; (B) xanthine/xanthine oxidase; (C) KO₂ in phosphate buffer solution-DMSO at pH 8.1 with argon to a solution of Fe(MGD)₂; (D) KO₂ in DEPMPO at pH 8.1 with argon to a solution of Fe(MGD)₂.
Reproduced with permission from [61] © The Royal Society of Chemistry.

Figure 20. Superoxide scavenging by spin trap and decomposition leads to NO release

Figure 21. Examples of lipophilic nitrones

Figure 22. Examples of esterified-nitrones

Figure 23. Lipophilic positively charged nitrones

Figure 24. Extracellular (CMPO) and amphiphilic nitrones

Figure 25. GS-PBN, GS-PPN and bio-SS-DMPO

Figure 26. Enhanced reactivity to $\text{O}_2^{\bullet-}$ by biconjugated DiAMPO

Figure 27. Resonance structures

The radical (A) anion and (B) cation showing the location of the unpaired electron.

Reproduced with permission from [187] © American Chemical Society.

Figure 28. Reduction in the left ventricular infarct size in untreated and DMPO-treated rat heart after ischemia and reperfusion using isolated heart Langendorff preparation

Reproduced with permission from [53] © American Society for Pharmacology and Experimental Therapeutics.

Figure 29. Effect of DMPO treatment on the protein expression of mitochondrial electron transport chain in the postischemic heart

Tissue homogenates of untreated and 1 mM DMPO-treated post-ischemic hearts were subjected to SDS-PAGE and then immunoblotted with antibodies against mitochondrial electron transport complex (A–D). The antibodies used are: anti-51 kDa (FMN-binding subunit) polyclonal antibody for complex I, anti-70 kDa (FAD-binding subunit) polyclonal antibody for complex II, and anti-CoX I and anti-CoX Vb monoclonal antibodies for complex IV.

I/R: Ischemic–reperfusion.

Reproduced with permission from [53] © American Society for Pharmacology and Experimental Therapeutics.

Table 1

Calculated spin and charge densities, and free energies, $G_{298K,aq}$, of addition to DMPO versus PBN at the Polarizable Continuum Model (water)/B3LYP/6-31+G(d,p)//B3LYP/6-31G(d) level of theory.

ROS	O(1) (kcal/mol)		O(2) (kcal/mol)		$G_{298K,aq}$ of addition (kcal/mol)	
	Spin (e)	Charge (e)	Spin (e)	Charge (e)	DMPO	PBN
O-O ⁻	0.50	-0.50	0.50	-0.50	11.9	18.3
HO(1)-O(2) [•]	0.27	-0.35	0.73	-0.15	-4.6	-0.9
HO(1)-O(2) ⁻	n/a	-0.68	n/a	-0.83	7.2	29.0
HO [•]	n/a	n/a	1.02	-0.50	-38.9	-31.2
HO ⁻	n/a	n/a	n/a	-1.46	9.0	14.6

DMPO: 5,5-dimethyl-1-pyrroline N-oxide.

Reproduced with permission from [116] © American Chemical Society.

Table 2

Average free energy of reaction G_{rxn} of radicals with nitrones at 298.15 K and their corresponding reduction potential E° .

Radical	Average G_{rxn} (kcal/mol)	Half reaction	E° , V	Ref.
$\text{HO}^{\bullet}$	-43.66	$\text{HO}^{\bullet}, \text{H}^+/\text{H}_2\text{O}$	2.31	[118]
$\text{CH}_3^{\bullet}$	-32.17	$\text{H}_3\text{CH}_2\text{C}^{\bullet}, \text{H}^+/\text{CH}_3\text{CH}_3$	1.90	[118]
$\text{HS}^{\bullet}$	-16.67	$\text{HS}^{\bullet}/\text{HS}^-$	0.92	[119]
$\text{HO}_2^{\bullet}$	-13.92	$\text{HO}_2^{\bullet}, \text{H}^+/\text{H}_2\text{O}_2$	1.06	[118]
$\text{O}_2^{\bullet-}$	-7.61	$\text{O}_2^{\bullet-}, 2\text{H}^+/\text{H}_2\text{O}_2$	0.94	[118]
NO	14.57	$\text{NO}/^3\text{NO}^-$	-0.80	[120]

Table 3

Reported experimental first-order half-lives of the $\text{O}_2^{\bullet-}$ adduct of cyclic nitrones.

Adducts	$t_{1/2}$ (min)	Ref.
DMPO-OOH	1.0	[111]
EMPO-OOH	8.6	[199]
DEPMPO-OOH	14	[200]
AMPO-OOH	9.9	[201]